abstract_id,session_title,abstract_title
719267,Oral Abstract Session A: Prostate Cancer,Final overall survival results from the EORTC 1333/PEACE-3 trial: Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.
719268,Oral Abstract Session A: Prostate Cancer,"Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway)."
719269,Oral Abstract Session A: Prostate Cancer,Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis.
719270,Oral Abstract Session A: Prostate Cancer,Fifteen-year survival analysis from the ASCENDE-RT randomized trial of external beam boost versus brachytherapy boost in localized prostate cancer.
719271,Trials in Progress Poster Session A: Prostate Cancer,Improving delivery of prostate cancer germline testing at the Department of Veterans Affairs: A cluster-randomized trial.
719272,"Treatment Selection, Response Assessment, and Monitoring Across the Spectrum of Advanced Prostate Cancer",Patient reported outcomes (PRO) and tolerability of capivasertib (capi) plus abiraterone (abi) versus placebo (pbo) plus abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): CAPItello-281.
719273,Trials in Progress Poster Session A: Prostate Cancer,"SOLACE: A phase 1 pharmacokinetic, dosimetry, safety, and dose optimization study for a single dose of 153Sm-DOTMP to treat metastatic bone pain."
719274,Trials in Progress Poster Session A: Prostate Cancer,Intermittent fasting in prostate cancer patients receiving androgen deprivation therapy.
719275,Trials in Progress Poster Session A: Prostate Cancer,"Triplet therapy with ADT, darolutamide, and biweekly docetaxel for high-risk metastatic castration-sensitive prostate cancer (TRIC): An open-label, single-arm phase II clinical trial."
719276,Trials in Progress Poster Session A: Prostate Cancer,A phase II study of luxdegalutamide in combination with abiraterone in adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).
719277,Trials in Progress Poster Session A: Prostate Cancer,"Phase 1, dose-escalation study of KTX-2001 (an NSD2 inhibitor) alone and in combination with darolutamide for metastatic castration-resistant prostate cancer."
719278,Trials in Progress Poster Session A: Prostate Cancer,Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102).
719279,Trials in Progress Poster Session A: Prostate Cancer,Internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors: The iLIVE trial.
719280,Trials in Progress Poster Session A: Prostate Cancer,AMPLIFY: A phase 3 study of 64Cu-SAR-bisPSMAÂ positron emission tomography in participants with biochemical recurrence of prostate cancer.
719281,Trials in Progress Poster Session A: Prostate Cancer,SPECTRA study: A phase II trial of supraphysiological androgen to enhance treatment activity with DNA-damaging agents in men with metastatic castration resistant prostate cancer (mCPRC).
719282,Trials in Progress Poster Session A: Prostate Cancer,Phase 2 expansion study of 212Pb-ADVC001 in metastatic prostate cancer: The TheraPb trial.
719283,Trials in Progress Poster Session A: Prostate Cancer,The LuxAR-02 phase II study of luxdegalutamide in combination with [177Lu]Lu-PSMA-617 in patients with prostate-specific membrane antigen (PSMA)â€“positive metastatic castration resistant prostate cancer (mCRPC).
719284,Trials in Progress Poster Session A: Prostate Cancer,A phase 1 study of docetaxel in combination with 177-lutetium-PSMA-I&amp;T in patients with metastatic castration-resistant prostate cancer.
719285,Trials in Progress Poster Session A: Prostate Cancer,Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate cancer.
719286,Trials in Progress Poster Session A: Prostate Cancer,MEVPRO-3: Phase III trial of mevrometostat plus enzalutamide (versus placebo plus enzalutamide) in metastatic castration-sensitive prostate cancer (mCSPC).
719287,Trials in Progress Poster Session A: Prostate Cancer,A study of GSK5458514 administered alone or in combination with other anticancer agents in patients with prostate cancer.
719288,Trials in Progress Poster Session A: Prostate Cancer,ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
719289,Trials in Progress Poster Session A: Prostate Cancer,Phase 1 dose escalation and expansion of AB001 in patients with metastatic castration resistant prostate cancer (mCRPC): The ARTISAN trial.
719290,Trials in Progress Poster Session A: Prostate Cancer,"OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response."
719291,Trials in Progress Poster Session A: Prostate Cancer,"ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC."
719292,Trials in Progress Poster Session A: Prostate Cancer,Dose optimisation and PSMA receptor intensification with 177Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial.
719293,Trials in Progress Poster Session A: Prostate Cancer,A phase II study of lutetium-177 DOTATATE in metastatic prostate cancer with neuroendocrine differentiation.
719294,Trials in Progress Poster Session A: Prostate Cancer,Nezastomig (anti-PSMAÃ—CD28) with or without cemiplimab (antiâ€“PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic clear cell renal cell carcinoma (mccRCC): A phase 1/2 study.
719295,Trials in Progress Poster Session A: Prostate Cancer,A pragmatic phase 2 trial of locally ablative therapy in oligo-progressive genitourinary (GU) tumors: LAYOVER
719296,Trials in Progress Poster Session A: Prostate Cancer,"IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer."
719297,Trials in Progress Poster Session A: Prostate Cancer,TulmiSTAR-01: A phase I/II dose optimization study of tulmimetostat in combination with luxdegalutamide versus standard of care (SOC) in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
719298,Trials in Progress Poster Session A: Prostate Cancer,Hypervigilance: A phase Ib clinical trial to optimize risk-benefit of nezastomig (PSMAxCD28 costimulatory bispecific antibody) plus cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC).
719299,Trials in Progress Poster Session A: Prostate Cancer,"IDeate-Prostate02: A phase 1/2, open-label umbrella substudy of ifinatamab deruxtecan-based treatment combinations or as monotherapy in participants with previously treated metastatic castration-resistant prostate cancer."
719300,Trials in Progress Poster Session A: Prostate Cancer,"TulmiSTAR-02: A phase I/II open-label study of dose escalation and expansion of tulmimetostat in combination with darolutamide versus darolutamide, and tulmimetostat with abiraterone in patients with metastatic hormone-sensitive prostate cancer (mHSPC)."
719301,Trials in Progress Poster Session A: Prostate Cancer,A phase I clinical trial of autologous gamma delta T cells genetically engineered with a chimeric receptor to target the prostate stem cell antigen in patients with metastatic castration-resistant prostate cancer.
719302,Trials in Progress Poster Session A: Prostate Cancer,OMAHA-004: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer (mCRPC) after a prior ARPI.
719303,Trials in Progress Poster Session A: Prostate Cancer,"Phase 2 study of ASP5541 (PRL-02), a long-acting intramuscular depot injection of abiraterone decanoate, in patients with advanced prostate cancer."
719304,Trials in Progress Poster Session A: Prostate Cancer,OMAHA-003: Phase 3 trial of CYP11A1 inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants (pts) with metastatic castration-resistant prostate cancer (mCRPC) after ARPI and taxane-based chemotherapy.
719305,Trials in Progress Poster Session A: Prostate Cancer,Radiation dose tailoring guided by enhanced targeting (RadTARGET): A multi-center randomized controlled trial.
719306,Trials in Progress Poster Session A: Prostate Cancer,"A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)."
719307,Trials in Progress Poster Session A: Prostate Cancer,Bladder full or empty for pelvic radiation therapy (BEFORE): A multi-center randomized controlled trial.
719308,Trials in Progress Poster Session A: Prostate Cancer,"Phase III, randomized, double-blind, placebo-controlled study of adjuvant saruparib (AZD5305) in patients with BRCAm localized high-risk prostate cancer who are receiving radiotherapy and androgen deprivation therapy (EvoPAR-Prostate02)."
719309,Trials in Progress Poster Session A: Prostate Cancer,CARPET trial: A phase II trial evaluating trastuzumab deruxtecan in metastatic castration-resistant prostate cancer.
719310,Trials in Progress Poster Session A: Prostate Cancer,A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: Protocol for a hybrid type I efficacy implementation trial.
719311,Trials in Progress Poster Session A: Prostate Cancer,Phase 3 study of 68Ga-PSMA-11 PET combined with MRI for the detection of prostate cancer (BIPASS).
719312,Trials in Progress Poster Session A: Prostate Cancer,Determining individual preferences for gynecomastia avoidance among men with prostate cancer: A qualitative study.
719313,Trials in Progress Poster Session A: Prostate Cancer,Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO).
719314,Poster Session A: Prostate Cancer,Treatment interruption guided by on-treatment prostate-specific membrane antigen (PSMA) PET/CT imaging in metastatic hormone-sensitive prostate cancer (mHSPC).
719315,Poster Session A: Prostate Cancer,PSMA PET versus conventional imaging in metastatic prostate cancer: Evaluation of disease volume classification in a veteran cohort.
719316,Trials in Progress Poster Session A: Prostate Cancer,Evaluation of the safety and efficacy of daily oral Angelica gigas Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial).
719317,Trials in Progress Poster Session A: Prostate Cancer,High-risk localized prostate cancer treated with neoadjuvant LHRH agonist/antagonist and enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo.
719318,Poster Session A: Prostate Cancer,New prostate cancer risk groups by PSMA-PET (PPP3).
719319,Trials in Progress Poster Session A: Prostate Cancer,"A randomized trial of neoadjuvant leuprorelin, darolutamide, or both prior to radical prostatectomy for intermediate- or high-risk prostate cancer."
719320,Poster Session A: Prostate Cancer,Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy.
719321,Poster Session A: Prostate Cancer,Radiographic recurrence patterns for prostate cancer with pathologic lymph node involvement following PSMA-PET and radical prostatectomy.
719322,Poster Session A: Prostate Cancer,Evaluation of ancillary multiparametric MRI features in PI-RADS 3 prostate lesions and their association with prostate cancer.
719323,Poster Session A: Prostate Cancer,TP53 mutations (TP53mut) as a predictive biomarker for lutetium-177-PSMA (Lu-PSMA) vs. docetaxel benefit in post-androgen receptor pathway inhibitors (ARPI) metastatic castration-resistant prostate cancer (mCRPC).
719324,Poster Session A: Prostate Cancer,Prevalence of treatment-acquired homozygous losses (homozygous deletions) of PTEN from androgen receptor pathway inhibitors (ARPI) in metastatic prostate cancer.
719325,Poster Session A: Prostate Cancer,Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: Descriptive post-hoc analysis from the phase 3 SPOTLIGHT study.
719326,Poster Session A: Prostate Cancer,Predicting cancer organ tropism in mCRPC patients using triple-tracer PET imaging radiomics clustering from the 3TMPO cohort study.
719327,Poster Session A: Prostate Cancer,An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy.
719328,Poster Session A: Prostate Cancer,Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data.
719329,Poster Session A: Prostate Cancer,Prospective monitoring of biochemically recurrent prostate cancer (BCR) using prostate specific membrane antigen (PSMA) imaging: 21-month follow-up.
719330,Poster Session A: Prostate Cancer,Detection of bone metastases in men with low PSA biochemical recurrence of prostate cancer with 18F-flotufolastat PET/CT: A post-hoc analysis from the phase 3 SPOTLIGHT study.
719331,Poster Session A: Prostate Cancer,Association of prostate specific antigen (PSA) doubling time (DT) and prostate specific membrane antigen (PSMA) findings in biochemically recurrent prostate cancer (BCR).
719332,Poster Session A: Prostate Cancer,Association of radiomic skeletal muscle features on prostate T1-weighted MRI with major adverse cardiac events in prostate cancer patients.
719333,Poster Session A: Prostate Cancer,Risk factors and treatment outcomes in metastatic prostate cancer with brain metastases.
719334,Poster Session A: Prostate Cancer,Survival outcomes with lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics.
719335,Poster Session A: Prostate Cancer,A novel method of analysis that uses standard of care PSA values to help guide optimal treatment decisions in the management of metastatic prostate cancer.
719336,Poster Session A: Prostate Cancer,Comparative risk of medication-related osteonecrosis of the jaw and survival outcomes with RANKL inhibitors versus bisphosphonates in metastatic prostate cancer.
719337,Poster Session A: Prostate Cancer,Mortality risk with androgen receptor pathway inhibitors: Real-world evidence.
719338,Poster Session A: Prostate Cancer,Artificial intelligenceâ€“based detection of treatment-emergent metastatic neuroendocrine carcinoma of prostate.
719339,Poster Session A: Prostate Cancer,Predictive role of peripheral blood erythroblasts for treatment intensification in metastatic hormone-sensitive prostate cancer.
719340,Poster Session A: Prostate Cancer,Outcomes of radium-223 therapy in combination with enzalutamide for metastatic castration-resistant prostate cancer: A multicenter retrospective analysis in Japan.
719341,Poster Session A: Prostate Cancer,"Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + darolutamide + docetaxel) for mHSPC: UK real world data from the RECOMMEND study."
719342,Poster Session A: Prostate Cancer,Real-world comparative effectiveness of novel doublet therapies for metastatic hormone-sensitive prostate cancer.
719343,Poster Session A: Prostate Cancer,Real-world outcomes of radium-223 in the FRONTIER study: Impact of prior up-front therapy in mCRPC.
719344,Poster Session A: Prostate Cancer,Treatment utilization among patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in real-world US settings: A prostate cancer disease observation (PRECISION) data platform analysis.
719345,Poster Session A: Prostate Cancer,Real-world utilization and timing of initiation of bone-targeting agents (BTAs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223: Results from Princess Margaret Cancer Centre (PM).
719346,Poster Session A: Prostate Cancer,Clinical outcomes among patients with metastatic hormone-sensitive prostate cancer in contemporary real-world US clinical practice: A prostate cancer disease observation (PRECISION) data platform analysis.
719347,Poster Session A: Prostate Cancer,Treatment patterns and survival outcomes among lutetium 177â€“experienced patients with metastatic castration-resistant prostate cancer.
719348,Poster Session A: Prostate Cancer,[177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in combination with an androgen receptor pathway inhibitor (ARPI) versus 177Lu-PSMA-617 alone for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.
719349,Poster Session A: Prostate Cancer,Real-world characteristics of long-term survivors with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): An analysis of the global REASSURE study.
719350,Poster Session A: Prostate Cancer,National trends and predictors of inpatient palliative care utilization in metastatic prostate cancer.
719351,Poster Session A: Prostate Cancer,Association of early achievement of ultra-low PSA levels with radiologic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC).
719352,Poster Session A: Prostate Cancer,High comorbidity as a predictor of poorer survival and ARPI efficacy in metastatic prostate cancer.
719353,Poster Session A: Prostate Cancer,Trends in PSA and metastatic prostate cancer at presentation in the United States from 2004-2022.
719354,Poster Session A: Prostate Cancer,Real-world effectiveness of systemic therapies after [177Lu]Lu-PSMA-617 (177Lu-PSMA-617)Â treatment in patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.
719355,Poster Session A: Prostate Cancer,Efficacy of 177Lu-PSMA-617 in neuroendocrine prostate cancer.
719356,Poster Session A: Prostate Cancer,Androgen-receptor pathway inhibitors triplet therapy (ARAAT): Real-world outcomes in metastatic hormone-sensitive prostate cancer.
719357,Poster Session A: Prostate Cancer,Long-term outcomes with radium-223 in metastatic castration resistant prostate cancer: US patient subset of the 10-year REASSURE global study.
719358,Poster Session A: Prostate Cancer,Association of MUTYH mutations with clinical outcomes in metastatic prostate cancer.
719359,Poster Session A: Prostate Cancer,Real-world use of novel hormonal therapies in European and North American patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
719360,Poster Session A: Prostate Cancer,Implementing comprehensive population-wide genomic testing in metastatic prostate cancer (mPCa): A real-world Canadian cohort study.
719361,Poster Session A: Prostate Cancer,Treatment and outcomes among patients with metastatic castrate resistant prostate cancer with an AR gene alteration: Analysis from the Kaiser Permanente Northern California Healthcare System.
719362,Poster Session A: Prostate Cancer,Real-world outcomes of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) in taxane-naÃ¯ve patients with metastatic castration-resistant prostate cancer (mCRPC): A prostate cancer disease observation (PRECISION) data platform analysis.
719363,Poster Session A: Prostate Cancer,Outcomes of cabazitaxel following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC).
719364,Poster Session A: Prostate Cancer,Treatment (Rx) patterns and attrition rates in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated between 2021-2025.
719365,Poster Session A: Prostate Cancer,Clinical and biomarker characteristics of treatment-emergent neuroendocrine prostate cancer.
719366,Poster Session A: Prostate Cancer,Outcomes of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) after sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC): A real-world prostate cancer disease observation (PRECISION) data platform analysis.
719367,Poster Session A: Prostate Cancer,Beyond BRCA: Real-world outcomes with poly(ADP-ribose) polymerase inhibitors among patients with metastatic castration-resistant prostate cancer and homologous recombination repair mutations.
719368,Poster Session A: Prostate Cancer,Durable outcomes in aggressive-variant prostate cancer treated with first-line carboplatinâ€“docetaxel: A 10-year tertiary centre experience.
719369,Poster Session A: Prostate Cancer,End-of-life treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
719370,Poster Session A: Prostate Cancer,Real-world utilization of tissue-free ctDNA monitoring in patients with prostate cancer.
719371,Poster Session A: Prostate Cancer,Association between metabolic syndrome and treatment outcomes in metastatic prostate cancer: A retrospective cohort analysis.
719372,Poster Session A: Prostate Cancer,Quantifying the hidden burden of metastatic prostate cancer.
719373,Poster Session A: Prostate Cancer,"Overall survival (OS) in elderly, frail, or high comorbidity veterans receiving androgen receptor pathway inhibitors (ARPIs) with androgen-deprivation therapy (ADT) vs ADT alone for de novo metastatic castration-sensitive prostate cancer (mCSPC)."
719374,Poster Session A: Prostate Cancer,Real-world treatment outcomes of advanced prostate cancer among Black compared to White men in the Medstar Health Network.
719375,Poster Session A: Prostate Cancer,Clinical outcomes in the real-world utilization of 177Lu-PSMA 617 in metastatic castrate-resistant prostate cancer.
719376,Poster Session A: Prostate Cancer,Sequencing of therapeutic agents before and after metastatic castration-resistant prostate cancer (mCRPC) diagnosis in an international real-world setting.
719377,Poster Session A: Prostate Cancer,Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure.
719378,Poster Session A: Prostate Cancer,Gaps in BRCA mutation testing among mCRPC patients: Insights from US cancer practices (2018â€“2024).
719379,Poster Session A: Prostate Cancer,Baseline biochemical and clinical predictors of castration resistance and survival in metastatic hormone-sensitive prostate cancer treated with first-line androgen receptor pathway inhibitors: A multicenter real-world study.
719380,Poster Session A: Prostate Cancer,"Early prostate specific antigen response and overall survival in metastatic hormone sensitive prostate cancer: Real-world data on age, body mass index, and treatment."
719381,Poster Session A: Prostate Cancer,Discontinuation rates among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating novel androgen receptor inhibitors in oncology and non-oncology settings.
719382,Poster Session A: Prostate Cancer,Treatment outcomes of patients (pts) with small cell or neuroendocrine carcinoma (SC/NE) of the prostate: A single-institution experience.
719383,Poster Session A: Prostate Cancer,Real-world comparison of prostate-specific antigen (PSA) response in metastatic castration-sensitive prostate cancer (mCSPC) patients treated with apalutamide (APA) without docetaxel vs darolutamide (DARO) without docetaxel.
719384,Poster Session A: Prostate Cancer,Comparative outcomes of RANKL inhibitors versus bisphosphonates in metastatic prostate cancer with bone metastases: A TriNetX real-world analysis.
719385,Poster Session A: Prostate Cancer,Comparison of quantitative functional RAD51 foci and genomic alterations in predicting PARPi response in mCRPC: A multicenter real-world study.
719386,Poster Session A: Prostate Cancer,Impact of androgen receptor pathway inhibitor (ARPI) dose reduction on overall survival of metastatic castration-resistant prostate cancer: A multi-centre retrospective study.
719387,Poster Session A: Prostate Cancer,Influence of concomitant distant lymph node metastases in metastatic hormone-sensitive prostate cancer patients with bone metastases.
719388,Poster Session A: Prostate Cancer,Post-operative pelvic lymph node radiation therapy in lymph node positive prostate cancer and mortality risk.
719389,Poster Session A: Prostate Cancer,Prevalence of major adverse cardiac events in men with prostate cancer receiving androgen deprivation therapy in real-world clinical practice.
719390,Poster Session A: Prostate Cancer,Real-world genomic analysis of chemerin in prostate cancer (PCa) and correlation with markers of immune infiltration and activation.
719391,Poster Session A: Prostate Cancer,Real-world darolutamide safety and effectiveness in nonmetastatic castration-resistant prostate cancer (nmCRPC) by lipid-modifying agent use: Post hoc analyses of DAROL interim analysis 4 (IA4).
719392,Poster Session A: Prostate Cancer,Aggressive variants and clinical patterns of progression in real-world metastatic hormone-sensitive prostate cancer (mHSPC).
719393,Poster Session A: Prostate Cancer,Severe acute kidney injury after abiraterone vs enzalutamide in advanced prostate cancer: A SEERâ€“Medicare study.
719394,Poster Session A: Prostate Cancer,"Quality of life, adherence, and adverse events among patients with advanced prostate cancer treated with relugolix: 6-month results of the OPTYX multicenter registry."
719395,Poster Session A: Prostate Cancer,Integration of genomic classification and clinical characteristics as a predictor of survival in de novo metastatic prostate cancer.
719396,Poster Session A: Prostate Cancer,Real-world ARPI utilization patterns and outcomes in metastatic castration-sensitive prostate cancer.
719397,Poster Session A: Prostate Cancer,Real-world survival disparities and comorbidity predictors with L<span>u-177â€“PSMA-617</span> and PARP inhibitors in metastatic prostate cancer.
719398,Poster Session A: Prostate Cancer,Real-world patient characteristics and treatment patterns among patients with metastatic castration-resistant prostate cancer treated with talazoparib plus enzalutamide in the US.
719399,Poster Session A: Prostate Cancer,Clinical characteristics and survival outcomes in veterans receiving radium-223 for metastatic castration-resistant prostate cancer.
719400,Poster Session A: Prostate Cancer,Contemporary analysis of the prognostic significance of intraductal carcinoma of the prostate (IDC-P).
719401,Poster Session A: Prostate Cancer,"A prospective, randomized, cross-over trial to assess patient preference for goserelin microsphere versus goserelin implant in prostate cancer: Interim results of the GOMIMP study."
719402,Poster Session A: Prostate Cancer,Real-world comparative outcomes of abiraterone vs enzalutamide in metastatic castration-sensitive prostate cancer (mCSPC): A propensity-matched analysis from the TriNetX Global Health Research Network.
719403,Poster Session A: Prostate Cancer,Harnessing caregiver support to improve shared decision-making in metastatic prostate cancer treatment: A US-based quantitative survey.
719404,Poster Session A: Prostate Cancer,Utilization of bone modifying agents in metastatic hormone resistant prostate cancer: A retrospective study of real world patients.
719405,Poster Session A: Prostate Cancer,Identifying and predicting non-cancer mortality risk in mHSPC following doublet therapy in the STAMPEDE trial.
719406,Poster Session A: Prostate Cancer,Adding metformin to androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): Quality of life (QoL) results from STAMPEDE.
719407,Poster Session A: Prostate Cancer,Predicting the risk of prostate cancer metastasis at diagnosis in the VA Health Care System from H&amp;E slides of the prostate needle biopsies.
719408,Poster Session A: Prostate Cancer,"Association between prostate cancer and mental health: A comparison across cancer types using the Medical Expenditure Panel Survey, 2017â€“2022."
719409,Poster Session A: Prostate Cancer,The association of androgen deprivation therapy with time to dementia: A large competing risk analysis.
719410,Poster Session A: Prostate Cancer,Comparative real-world survival and prescription patterns of darolutamide versus apalutamide in non-metastatic hormone-resistant prostate cancer.
719411,Poster Session A: Prostate Cancer,Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer: From the ARASENS trial.
719412,Poster Session A: Prostate Cancer,Quality of life assessment during prostate cancer radionuclide therapy: Updated FACT-RNT psychometric evaluation.
719413,Poster Session A: Prostate Cancer,SPPADE symptom burden and ePRO-based outcome prediction in patients with mCRPC treated with 177Lu-PSMA-617 (LuPSMA).
719414,Poster Session A: Prostate Cancer,Bone fractures with androgen pathway inhibitors (ARPi) in patients (pts) with prostate cancer (PCa): A systematic review and network meta-analysis.
719415,Poster Session A: Prostate Cancer,"Safety profile of darolutamide + ADT compared to enzalutamide, apalutamide, and abiraterone in metastatic castration-sensitive prostate cancer: Results from the first safety matching-adjusted indirect comparison."
719416,Poster Session A: Prostate Cancer,Development of cardiovascular disease risk factors in patients with prostate cancer initiating novel hormonal therapies (NHTs): Real world evidence.
719417,Poster Session A: Prostate Cancer,Changes in CTCAE v6: Effect on dose-escalation and dose-limiting toxicity with repeat analysis of recent clinical trials.
719418,Poster Session A: Prostate Cancer,Renal outcomes following 177Lu-PSMA-617 (LuPSMA) in patients with metastatic castration-resistant prostate cancer (MCRPC).
719419,Poster Session A: Prostate Cancer,Effects of a diet high in omega-3 polyunsaturated fatty acids (PUFAs) on inhibition of soluble epoxide hydrolase (sEH) and mitigation of painful docetaxel-induced peripheral neuropathy in mice.
719420,Poster Session A: Prostate Cancer,Prognostic significance of depressive symptoms in men with advance prostate cancer (PC): Results from the IRONMAN registry.
719421,Poster Session A: Prostate Cancer,ARTEMIS-003: A phase 2 study of HS-20093 (GSK5764227) in patients with metastatic castration-resistant prostate cancer (mCRPC).
719422,Poster Session A: Prostate Cancer,EXTRA-PC: A phase II trial of masofaniten (EPI-7386) and enzalutamide with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).
719423,Poster Session A: Prostate Cancer,Cardiovascular toxicity with androgen-receptor pathway inhibitors in metastatic prostate cancer: A meta-analysis of randomized trials.
719424,Poster Session A: Prostate Cancer,Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with genitourinary extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
719425,Poster Session A: Prostate Cancer,ARTO trial (NCT03449719): Long-term overall survival analysis from a randomized phase II trial testing the benefit of stereotactic body radiotherapy addition to abiraterone acetate in oligometastatic castrate resistant prostate cancer patients.
719426,Poster Session A: Prostate Cancer,Impact of abiraterone versus enzalutamide on depression and anxiety in hormone-sensitive prostate cancer (HSPC).
719427,Poster Session A: Prostate Cancer,Impact of lutetium Lu 177 vipivotide tetraxetan on prostate cancer outcomes by race.
719428,Poster Session A: Prostate Cancer,Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer.
719429,Poster Session A: Prostate Cancer,A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL).
719430,Poster Session A: Prostate Cancer,3-weekly docetaxel 75 mg/m2 vs 2-weekly docetaxel 50 mg/m2 in combination with darolutamide + ADT in patients with mHSPC: Subgroup analyses from the randomised phase 3 ARASAFE trial.
719431,Poster Session A: Prostate Cancer,"A phase 1/2 study of MRT-2359, a highly selective oral GSPT1 molecular glue degrader (MGD), in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) harboring AR ligand binding domain (LBD) mutations."
719432,Poster Session A: Prostate Cancer,"A clinical, evidence-based risk estimator for individualizing benefit and response in oligometastatic prostate cancer (CEREBRO): A tool from the X-Met collaboration."
719433,Poster Session A: Prostate Cancer,"Circulating tumor DNA (ctDNA) dynamics in bone-dominant metastatic castration resistant prostate cancer (mCRPC) treated with radium-223 with or without olaparib: Biomarker analyses from the multicenter, randomized, phase 2, investigator-initiated COMRADE trial."
719434,Poster Session A: Prostate Cancer,A phase 1b/2 study of FOR46 in combination with enzalutamide (enza) in patients with metastatic castration resistant prostate cancer (mCRPC).
719435,Poster Session A: Prostate Cancer,"Evaluation of PSA decline patterns in the Chinese subgroup of LIBERTAS, a phase 3 study of apalutamide plus continuous versus intermittent androgen deprivation therapy in metastatic castration-sensitive prostate cancer."
719436,Poster Session A: Prostate Cancer,Trial design and objectives for prostate cancer: Recommendations from the Prostate Cancer Clinical Trials Working Group 4 (PCWG4).
719437,Poster Session A: Prostate Cancer,"PERSIAN trial (NCT03449719): Predictive features of complete biochemical response within a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer."
719438,Poster Session A: Prostate Cancer,Safety data from UPLIFT: Phase I/II study of CDK4/6 inhibition with abemaciclib to upregulate PSMA expression prior to 177Lu-PSMA-617 treatment in patients with metastatic castrate resistant prostate cancer (mCRPC).
719439,Poster Session A: Prostate Cancer,Clinical implications of prostate specific antigen (PSA) flare and response dynamics in TALAPRO-2: A post-hoc analysis.
719440,Poster Session A: Prostate Cancer,Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON.
719441,Poster Session A: Prostate Cancer,Immunotherapy in intermediate-risk biochemically recurrent prostate cancer (BCR): The National Cancer Institute experience.
719442,Poster Session A: Prostate Cancer,"Phase 1 safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of pasritamig in Asian population with metastatic castration-resistant prostate cancer (mCRPC)."
719443,Poster Session A: Prostate Cancer,Pharmacokinetics and dosimetry of lutetium Lu 177 zadavotide guraxetan in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the ECLIPSE sub-study.
719444,Poster Session A: Prostate Cancer,A phase 1b/2 study to evaluate the safety and efficacy of igermetostat (XNW5004) in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.
719445,Poster Session A: Prostate Cancer,Skeletal muscle index as a prognostic and predictive biomarker in de novo hormone sensitive prostate cancer: An exploratory analysis of the STAMPEDE trials.
719446,Poster Session A: Prostate Cancer,"ProTACT: A first-in-human, phase 1 study evaluating the safety, tolerability, and anti-tumor activity of [225Ac]Ac-FL-020, an anti-PSMA radioconjugate in patients with mCRPC."
719447,Poster Session A: Prostate Cancer,Clinical validity of FoundationOne CDx assay to identify HRR-positive or BRCA-positive mCSPC patients in the phase 3 AMPLITUDE study.
719448,Poster Session A: Prostate Cancer,DB-1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated mCRPC from a phase 1/2 study: Analyses according to prior treatment with lutetium 177 (177Lu)-PSMA-617.
719449,Poster Session A: Prostate Cancer,Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study.
719450,Poster Session A: Prostate Cancer,Darolutamide plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC): ARASEC â€“ US prospective open-label phase 2 study with an external control arm.
719451,Poster Session A: Prostate Cancer,Updated efficacy results from the phase 1 study of gotistobart (BNT316/ONC-392) in combination with lutetium Lu 177 vipivotide tetraxetan (Lu 177) in patients with metastatic castration-resistant prostate cancer (mCRPC).
719452,Poster Session A: Prostate Cancer,Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castrationâ€‘sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data.
719453,Poster Session A: Prostate Cancer,Efficacy and safety of darolutamide and ADT in patient subgroups by baseline comorbidities and concomitant medications: ARANOTE post hoc analyses.
719454,Poster Session A: Prostate Cancer,Saruparib + androgen receptor pathway inhibitor (ARPI) + androgen deprivation therapy (ADT) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): The phase 1/2 PETRANHA trial.
719455,Poster Session A: Prostate Cancer,The efficacy and safety of 177Lu-PSMA-617 in Chinese patients with post-taxane metastatic castration-resistant prostate cancer: From a multicenter phase II study.
719456,Poster Session A: Prostate Cancer,Comparison of docetaxel triplet therapy with androgen receptor pathway inhibitor (ARPI) doublet in US veterans with metastatic hormone sensitive prostate cancer (mHSPC).
719457,Poster Session A: Prostate Cancer,Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
719458,Poster Session A: Prostate Cancer,Metastatic lesion location and avidity on baseline PSMA PET/CT as predictor of duration of Lu177 treatment in men with metastatic castrate resistant prostate cancer.
719459,Poster Session A: Prostate Cancer,"A multicohort phase 2 trial of androgen deprivation therapy (ADT), docetaxel (DOCE), and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumors and DNA damage repair (DDR) alterations."
719460,Poster Session A: Prostate Cancer,Feasibility and outcomes of response-adapted and retreatment 177Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
719461,Poster Session A: Prostate Cancer,Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK examining sustained prostate-specific antigen (PSA) &lt;0.2 ng/mL despite testosterone (T) recovery after treatment (tx) suspension.
719462,Poster Session A: Prostate Cancer,A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis.
719463,Poster Session A: Prostate Cancer,Impact of baseline hot flashes on sleep metrics during initial treatment in LIBERTAS clinical trial.
719464,Poster Session A: Prostate Cancer,Estimated net benefit of talazoparib (TALA) + enzalutamide (ENZA) for patients (Pts) with mCRPC using a Q-TWiST analysis.
719465,Poster Session A: Prostate Cancer,Long-term clinical outcomes and genomic predictors of PSMA-PET/CT-guided cytoreductive progression-directed therapy in patients with oligoprogressive castration-resistant prostate cancer.
719466,Poster Session A: Prostate Cancer,Novel androgen receptor inhibitors for the treatment of metastatic castration-sensitive prostate cancer: A cost-effectiveness analysis.
719467,Poster Session A: Prostate Cancer,"Results of a prospective, single-center phase-II study on modern androgen deprivation therapy followed by cytoreductive radical prostatectomy in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC)."
719468,Poster Session A: Prostate Cancer,Redefining multimodal treatment in high-volume metastatic hormone-sensitive prostate cancer: Prospective evidence for robot-assisted cytoreductive prostatectomy following triplet systemic therapy.
719469,Poster Session A: Prostate Cancer,Efficacy and safety of mevrometostat (M) in combination with enzalutamide (E) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Data from a phase 1 study.
719470,Poster Session A: Prostate Cancer,Efficacy of rezvilutamide in preventing the flare phenomenon induced by GnRH agonists in newly diagnosed metastatic hormone-sensitive prostate cancer: An exploratory multicenter randomized controlled trial.
719471,Poster Session A: Prostate Cancer,Influence of body composition on the efficacy of chemotherapy in men with metastatic aggressive variant prostate cancer (AVPC).
719472,Poster Session A: Prostate Cancer,Radium 223 without androgen deprivation therapy (ADT) in patients (Pts) with biochemically recurrent prostate cancer (BCR) and PET findings in the bones.
719473,Poster Session A: Prostate Cancer,"Direct comparative and network meta analysis of PARP inhibitor and androgen receptor targeted therapies in first line mCRPC: Defining the optimal regimen among 8,997 patients."
719474,Poster Session A: Prostate Cancer,Overall survival in men with metastatic castration-resistant prostate cancer treated with olaparib or lutetium-177-PSMA-617 following prior systemic therapy.
719475,Poster Session A: Prostate Cancer,Switch androgen receptor pathway inhibitor strategies in metastatic castration-resistant prostate cancer: A meta-analysis of randomized trials.
719476,Poster Session A: Prostate Cancer,Metformin effects on renal function in mCRPC during PSMA radiopharmaceutical therapy (RPT): A retrospective analysis.
719477,Poster Session A: Prostate Cancer,Shifting 177Lu-PSMA-617 upstream in mCRPC: A meta-analysis of randomized trials stratified by taxane exposure.
719478,Poster Session A: Prostate Cancer,Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: Phase II single-arm trial (the CIPHER trial).
719479,Poster Session A: Prostate Cancer,Development and validation of computational histology artificial intelligence (CHAI)â€“powered prognostic and predictive biomarkers in metastatic hormone-sensitive prostate cancer (mHSPC) using ENZAMET and CHAARTED prospective randomized phase 3 trials (RCT).
719480,Poster Session A: Prostate Cancer,Efficacy and safety of Lu-177-DGUL in a phase 2 study of patients with metastatic castration-resistant prostate cancer (mCRPC).
719481,Poster Session A: Prostate Cancer,Effect of enzalutamide and bipolar androgen therapy on clonal hematopoiesis and clinical outcomes among men with metastatic castration resistant prostate cancer.
719482,Poster Session A: Prostate Cancer,Clinical and demographic disparities in prostate cancer patients undergoing radical prostatectomy: A 20-year retrospective cohort study from the United States.
719483,Poster Session A: Prostate Cancer,Evaluation of toxicity profiles of next-generation androgen receptor pathway inhibitors in the geriatric population: Analysis of the FAERS (FDA Adverse Event Reporting System) database.
719484,Poster Session A: Prostate Cancer,Opening the black box: Biologic pathways underlying multimodal digital-pathology artificial intelligence in metastatic prostate cancer.
719485,Poster Session A: Prostate Cancer,Prognostic utility of neutrophil:lymphocyte ratio (NLR) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration resistant prostate cancer (mCRPC).
719486,Poster Session A: Prostate Cancer,Comprehensive genomic profiling in prostate cancer: Clinical relevance of BRCA1/2 pathogenic variants in the mCRPC.
719487,Poster Session A: Prostate Cancer,Patient-reported outcomes (PRO) from a dose-escalation and expansion trial of fractionated and multiple-cycle PSMA-targeted alpha radionuclide 225Ac-J591.
719488,Poster Session A: Prostate Cancer,Genomic profiling in circulating tumor DNA from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer: The KYUCOG-1901 study.
719489,Poster Session A: Prostate Cancer,Real-world evaluation of olaparib combined with novel hormone therapy in metastatic castration-resistant prostate cancer with intraductal adenocarcinoma.
719490,Poster Session A: Prostate Cancer,Adiposity and response to ADT Â± AR pathway inhibitors (ARPI) in men with metastatic hormone-sensitive prostate cancer (mHSPC).
719491,Poster Session A: Prostate Cancer,Heterogeneity and synergistic inhibition of the poly(ADP-ribose) polymerase and androgen receptor signaling pathway in patients with metastatic castration-resistant prostate cancer.
719492,Poster Session A: Prostate Cancer,Investigation of the PORTOS gene expression signature and the benefit of docetaxel in the ECOG-ACRIN E3805 CHAARTED randomized trial.
719493,Poster Session A: Prostate Cancer,"TRIM28-mediated SUMOylation of ERG at K389 and its association with cell proliferation, PARP inhibitor response, and 53BP1 expression in castration-resistant prostate cancer."
719494,Poster Session A: Prostate Cancer,Machine learning models combining 68Ga-PSMA PET radiomics and clinical features to predict overall survival for mCRPC patients treated with 177Lu-PSMA radioligand therapy.
719495,Poster Session A: Prostate Cancer,Plasma cell-free DNA methylation as a predictive biomarker for hormonal therapy response in advanced prostate cancer.
719496,Poster Session A: Prostate Cancer,Obesity-associated epigenetic remodeling under androgen deprivation therapy: Implications for cardiometabolic risk in prostate cancer.
719497,Poster Session A: Prostate Cancer,Effects of obesity on biphasic immune remodeling of CD45âº circulating cells during androgen deprivation therapy in prostate cancer.
719498,Poster Session A: Prostate Cancer,Effects of 3Î²-HSD1 on back-conversion and androgen signaling in CRPC.
719499,Poster Session A: Prostate Cancer,Liquid biopsy for detection of DDR gene alterations in metastatic prostate cancer (mPC): Diagnostic performance and clinical correlations.
719500,Poster Session A: Prostate Cancer,Extracellular vesicles (EVs) and circulating tumor DNA (ctDNA) as potential biomarkers of response to 177Lu-PSMA-617.
719501,Poster Session A: Prostate Cancer,Predictive value of a pathomics signature in de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase 3 trial.
719502,Poster Session A: Prostate Cancer,Therapy-resistant subclones as drivers of progression in aggressive variant prostate cancer.
719503,Poster Session A: Prostate Cancer,Homologous recombination repair (HRR) mutation in de novo metastatic hormone sensitive prostate cancer (mHSPC).
719504,Poster Session A: Prostate Cancer,Clinical characteristics and molecular evolution of treatment-emergent small-cell/neuroendocrine prostate cancer in the era of doublet and triplet systemic therapy.
719505,Poster Session A: Prostate Cancer,A prospective study exploring genomic correlates of clinical outcome in patients with metastatic castration-sensitive prostate cancer receiving enzalutamide.
719506,Poster Session A: Prostate Cancer,Homologous recombination deficiency signature (HRDsig) status in BRCA1/2 wild type (BRCA1/2wt) clinically advanced prostate cancer (CAPC).
719507,Poster Session A: Prostate Cancer,Body composition metrics and clinical outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177â€“PSMA-617.
719508,Poster Session A: Prostate Cancer,Non-invasive prostate cancer subtyping using 5hmC-sequencing of cell-free DNA.
719509,Poster Session A: Prostate Cancer,Profiling BCRAness phenotype in public prostate cancer datasets without homologous repair gene mutations.
719510,Poster Session A: Prostate Cancer,Epigenomic alterations associated with androgen receptor pathway inhibitor response in metastatic castration-resistant prostate cancer.
719511,Poster Session A: Prostate Cancer,Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer.
719512,Poster Session A: Prostate Cancer,Examination of Decipher prostate genomic classifier in patients with de novo metastatic disease from a large scale real-world clinical and transcriptomic data linkage.
719513,Poster Session A: Prostate Cancer,Age as modifier of early proteomic remodeling after androgen deprivation therapy (ADT) in prostate cancer: Influence of innate immune/complementâ€“ECM pathways.
719514,Poster Session A: Prostate Cancer,"Predictive associations between serum oxo-androgens, race, and radiographic progression-free survival (rPFS) among patients treated with apalutamide (Apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study."
719515,Poster Session A: Prostate Cancer,Early prediction of PSA nadir in metastatic castration-sensitive prostate cancer with machine learning approaches.
719516,Poster Session A: Prostate Cancer,Development of a putative liquid biopsy gene panel for predicting liver metastasis in castration-resistant prostate cancer.
719517,Poster Session A: Prostate Cancer,Gut microbiome (GMB) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair alterations (HRRm) treated with PARP inhibitor (PARPi) therapy.
719518,Poster Session A: Prostate Cancer,Incidence and co-occurrence of targetable key genomic alterations (GenAlt) in metastatic prostate cancer (mPC): Preliminary results from the prostate cancer cohort of the FPG500 program.
719519,Poster Session A: Prostate Cancer,The diversity and clinical relevance of germline DNA damage repair gene variants in 3005 patients with metastatic prostate cancer.
719520,Poster Session A: Prostate Cancer,Cardiometabolic healthâ€™s influence on outcomes in men with localized high-risk prostate cancer (HRPCa) treated with pre-operative ADT Â± AR pathway inhibition (ARPI).
719521,Poster Session A: Prostate Cancer,A liquid biopsy targeted proteomic assay to predict outcomes in castration resistant prostate cancer patients treated with 177Lu-PSMA-617.
719522,Poster Session A: Prostate Cancer,Prospective comparison of AR-V7 transcripts from whole blood and circulating tumor cells in castration-resistant prostate cancer patients undergoing treatment with androgen-receptor signaling inhibitors: The PEARL trial.
719523,Poster Session A: Prostate Cancer,"Establishment and characterization of a panel of prostate adenocarcinoma XPDX models representing naÃ¯ve, chemotherapy- and radiotherapy-resistant patient populations."
719524,Poster Session A: Prostate Cancer,Plasma cfChIP-seq to predict cell surface target expression in neuroendocrine prostate cancer.
719525,Poster Session A: Prostate Cancer,Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).
719526,Poster Session A: Prostate Cancer,Characterization of HER2 expression in prostate cancer compared with other solid tumors.
719527,Poster Session A: Prostate Cancer,Structural classification of FOXA1 alterations and their association with clinical outcomes in prostate cancer patients: A multi-institutional retrospective analysis.
719528,Poster Session A: Prostate Cancer,Genetic ancestry and stage-specific differences in prostate cancer genomic alterations.
719529,Poster Session A: Prostate Cancer,Prognostic and genomic implications of HER2 expression in metastatic prostate cancer.
719530,Poster Session A: Prostate Cancer,Combining PSMA-PET metrics and circulating tumor cell RNA sequencing to predict LuPSMA response.
719531,Poster Session A: Prostate Cancer,Tumor microenvironmental NRG1 activation of HER3 as a driver of resistance to PI3K pathway inhibition in prostate cancer.
719532,Poster Session A: Prostate Cancer,CCL21 as a treatment-linked prognostic biomarker in metastatic castration-resistant prostate cancer.
719533,Poster Session A: Prostate Cancer,Optimizing neoadjuvant ADT duration prior to radiotherapy in high-risk prostate cancer: Rationale and clinical need.
719534,Poster Session A: Prostate Cancer,Serial proteomic characterization of plasma extracellular vesicles (EV) to identify changes that predict outcomes in metastatic castrate-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA-617.
719535,Poster Session A: Prostate Cancer,A phase 2 trial of darolutamide to enhance prostate-specific membrane antigen expression in patients with localized prostate cancer (Daro-PET).
719536,Poster Session A: Prostate Cancer,Noninvasive fragmentomic profiling of plasma cell-free DNA (cfDNA) in metastatic prostate cancer (mPC): Associations with transcriptomic phenotypes and disease states.
719537,Poster Session A: Prostate Cancer,Diagnostic performance of 18F-flotufolastat PET/CT compared with conventional imaging for detection of pelvic lymph node metastases in men with newly diagnosed prostate cancer: Descriptive post-hoc analysis from the phase 3 LIGHTHOUSE study.
719538,Poster Session A: Prostate Cancer,Inherited risk for prostate cancer (PCa): Following the natural history of men with increased genetic risk using multiparametric MRI (mpMRI).
719539,Poster Session A: Prostate Cancer,Aggressive-variant prostate cancer features and therapeutic outcomes in patients with de-novo metastatic hormone-sensitive prostate cancer.
719540,Poster Session A: Prostate Cancer,Micro-ultrasound compared with MRI-targeted biopsy in detecting clinically significant prostate cancer: Systematic review and meta-analysis.
719541,Poster Session A: Prostate Cancer,Enhancing post-HIFU surveillance: Diagnostic performance of 18F-PSMA PET/CT and mpMRI for local prostate cancer recurrence.
719542,Poster Session A: Prostate Cancer,Comparison of multiparametric prostate MRI (mpMRI) vs. positive biopsy cores on risk of adverse pathologic outcomes after radical prostatectomy (RP) in Gleason grade group (GG) 2 prostate cancer.
719543,Poster Session A: Prostate Cancer,Effect of a one-time sensitive screening intervention on prostate cancer mortality: The STHLM3 randomized trial.
719544,Poster Session A: Prostate Cancer,Stockholm3-MRI population-based screening: Two-year outcomes comparing Stockholm3 and PSA.
719545,Poster Session A: Prostate Cancer,The clinical impact of germline variants in DNA repair genes in patients who underwent curative surgery for localized prostate cancer.
719546,Poster Session A: Prostate Cancer,Rethinking germline testing in localized prostate cancer: Prevalence of germline variants and association with Gleason score and NCCN risk grouping.
719547,Poster Session A: Prostate Cancer,Prostate cancer screening in a geriatric population.
719548,Poster Session A: Prostate Cancer,Predictive capability of combining ExoDx (EPI) and pre-biopsy prostate MRI in detecting clinically significant prostate cancer in African American men.
719549,Poster Session A: Prostate Cancer,Is it time to redefine the Phoenix criterion for biochemical failure in the era of PSMA PET/CT?
719550,Poster Session A: Prostate Cancer,Impact of piflufolastat F18 imaging on disease management for prostate cancer patients: Observations from the PYLARIFY Registry study.
719551,Poster Session A: Prostate Cancer,Patient (pt) preferences for treatment (tx) of non-metastatic hormone-sensitive prostate cancer (nmHSPC): A discrete choice experiment (DCE).
719552,Poster Session A: Prostate Cancer,"From innovation to evidence: Trends in AI/ML clinical trials in GU oncology, 2010-2025."
719553,Poster Session A: Prostate Cancer,The impact of the 2025 NCCN update in defining very high-risk prostate cancer on surgical outcomes after robot-assisted radical prostatectomy: A retrospective cohort analysis.
719554,Poster Session A: Prostate Cancer,Trends in high grade prostate cancer at diagnosis in the United States from 2004-2022.
719555,Poster Session A: Prostate Cancer,Biopsy patterns following high intensity focused ultrasound as assessed by CAPRA score.
719556,Poster Session A: Prostate Cancer,Four-year outcomes of a genetic-based screening protocol for prostate cancer: Unveiling the Italian paradox.
719557,Poster Session A: Prostate Cancer,Predictive value of Gleason pattern 4 length on adverse surgical pathology and oncologic outcomes.
719558,Poster Session A: Prostate Cancer,Real-world clinical outcomes among patients with localized prostate cancer (LPC) undergoing radical prostatectomy (RP).
719559,Poster Session A: Prostate Cancer,"The practice of active surveillance for prostate cancer: Trends, variation, and quality within a large national health system."
719560,Poster Session A: Prostate Cancer,Salvage radiotherapy after radical prostatectomy in a Japanese cohort: Analysis from the MICAN study.
719561,Poster Session A: Prostate Cancer,Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.
719562,Poster Session A: Prostate Cancer,Association between genomic classifier scores and initial management of localized prostate cancer in a population-based cohort in the United States.
719563,Poster Session A: Prostate Cancer,Long-term oncological outcomes of prostate cancer upgrading following robot-assisted radical prostatectomy.
719564,Poster Session A: Prostate Cancer,Pelvic lymph node risk stratification in prostate cancer: A machine learning approach toward a predictive nomogram.
719565,Poster Session A: Prostate Cancer,Polypharmacy and potential drugâ€“drug interactions with novel androgen receptor signaling inhibitors (ARSIs) in patients (pts) with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC) in a real-world setting.
719566,Poster Session A: Prostate Cancer,Impact of GLP1 receptor agonists on severity of prostate cancer at diagnosis: A propensity score weighted analysis.
719567,Poster Session A: Prostate Cancer,Early-onset prostate cancer: A time series analysis of age-stratified trends.
719568,Poster Session A: Prostate Cancer,Plant-based dietary indices and quality of life in men with prostate cancer.
719569,Poster Session A: Prostate Cancer,Cardio-kidney-metabolic syndrome and prostate cancer: Prognostic significance of higher stages for cardiovascular morbidity and mortality.
719570,Poster Session A: Prostate Cancer,Germline radiosensitivity biomarker for radiation-induced GU toxicity following radiation therapy in localized prostate cancer (GARUDA): Two-year outcomes of a phase II clinical trial.
719571,Poster Session A: Prostate Cancer,Association between preoperative glycemic control and outcomes after radical prostatectomy.
719572,Poster Session A: Prostate Cancer,Real-world determinants of testosterone recovery following androgen deprivation therapy in patients with localized prostate cancer.
719573,Poster Session A: Prostate Cancer,Differential quality of life (QoL) with novel hormonal therapy (NHT) in metastatic castration-sensitive prostate cancer (mCSPC): A network meta-analysis of randomized clinical trials.
719574,Poster Session A: Prostate Cancer,"A randomised, multicentre, phase II trial of active surveillance with or without six months of apalutamide for prostate cancer."
719575,Poster Session A: Prostate Cancer,Randomized pilot trial of pre-visit patient education as preparation for decision making in newly diagnosed prostate cancer (PrepDM).
719576,Poster Session A: Prostate Cancer,Prospective evaluation of sexual function over 5 years in patients with localized prostate cancer treated with carbon-ion radiotherapy.
719577,Poster Session A: Prostate Cancer,Using large language models for grading CTCAE toxicity after radiation therapy for prostate cancer.
719578,Poster Session A: Prostate Cancer,The therapeutic efficacy of radical prostatectomy and external beam radiation therapy in patients with histologic variants of prostate cancer.
719579,Poster Session A: Prostate Cancer,CT- vs 1.5T MR-guidance in salvage radiotherapy of locally recurrent prostate cancer after radical prostatectomy.
719580,Poster Session A: Prostate Cancer,Perioperative outcomes from a randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robot-assisted radical prostatectomy (RARP).
719581,Poster Session A: Prostate Cancer,SAVE: A multicenter randomized phase 2 trial of salvage radiotherapy (SRT) with androgen-deprivation therapy (ADT) versus apalutamide (Apa) for biochemical progression after radical prostatectomy (RP).
719582,Poster Session A: Prostate Cancer,"Interim safety analysis of a randomized phase II trial comparing pembrolizumab with radiation versus pembrolizumab, olaparib, and radiation in localized high risk prostate cancer."
719583,Poster Session A: Prostate Cancer,Angelica herbal supplement AGN-Cogni.Q acute dose safety and pharmacokinetics (PK) dose-response in prostate cancer patients.
719584,Poster Session A: Prostate Cancer,Impact of intraoperative frozen section analysis (NeuroSAFE) on oncologic and functional outcomes after radical prostatectomy: A systematic review and meta-analysis.
719585,Poster Session A: Prostate Cancer,The impact of rising PSA during salvage radiotherapy post radical prostatectomy on relapse.
719586,Poster Session A: Prostate Cancer,A feasibility trial investigating inductive apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer: First results of the prospective phase II INDUCTA study.
719587,Poster Session A: Prostate Cancer,Prostate cancer: Correlating the clinical phenotype to the genotype.
719588,Poster Session A: Prostate Cancer,"Efficacy, safety, and cost-effectiveness of reduced vs. full initial dose androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer: A multicenter retrospective study."
719589,Poster Session A: Prostate Cancer,Association of a post-prostatectomy digital pathologyâ€“based multimodal artificial intelligence (MMAI) biomarker with nodal and extrapelvic metastasis on PET/CT at the time of biochemical recurrence and event-free survival following salvage radiotherapy.
719590,Poster Session A: Prostate Cancer,Role of urinary exosomal FAM153C-RPL19 in detection and risk stratification of prostate cancer: A multicentre Chinese cohort study.
719591,Poster Session A: Prostate Cancer,Prognostic value and clinical utility of a six-gene signature for aggressive prostate cancer among clinically low or intermediate risk patients.
719592,Poster Session A: Prostate Cancer,"Comprehensive analysis of androgen production, uptake, and conversion (APUC) genes to highlight SRD5 family diversity in a large localized prostate cancer cohort."
719593,Poster Session A: Prostate Cancer,Synergistic efficacy of gedatolisib and darolutamide in prostate cancer to overcome resistance to androgen-targeted therapy.
719594,Poster Session A: Prostate Cancer,"MRI-targeted biopsy with index lesion ipsilateral or bilateral systematic biopsy in prostate cancer: A multicenter, paired, noninferiority, observational trial."
719595,Poster Session A: Prostate Cancer,Enhancing the molecular assessment of MRI targeted prostate biopsies utilizing near real time stimulated Raman histology and artificial intelligence.
719596,Poster Session A: Prostate Cancer,Deep spatial analysis of the tumor-immune interface in localized prostate cancer.
719597,Poster Session A: Prostate Cancer,Spatially resolved HER2 and AR expression in prostate cancer and its implications for HER2 as a distinct therapeutic target.
719598,Poster Session A: Prostate Cancer,Clinical outcomes of patients with grade group 1 prostate cancer with extraprostatic extension: Results from up to 25 years of follow-up.
719599,Poster Session A: Prostate Cancer,Genomic risk classifier performance in PET-guided post-prostatectomy patients: Secondary analysis of a randomized trial.
719600,Poster Session A: Prostate Cancer,Microplastics and prostate cancer.
719601,Poster Session A: Prostate Cancer,"Concordance between clinical, genomic, and AI-based risk stratification in prostate cancer."
719602,Poster Session A: Prostate Cancer,Insulin pathway changes in localized prostate cancer: A multi-institutional analysis.
719603,Poster Session A: Prostate Cancer,Remodeling of the periprostatic adipose microenvironment in aggressive prostate cancer: Insights from a multi-institutional atlas-based geometric analysis.
719604,Poster Session A: Prostate Cancer,FAP+FN1+CAV1+ cancer-associated fibroblast subtype and its association with aggressive behavior in localized prostate cancer.
719605,Poster Session A: Prostate Cancer,The Prolaris test on diagnostic biopsy for localized prostate cancer prognosis across risk groups and management: An individual participant data meta-analysis.
719606,Poster Session A: Prostate Cancer,Histologic predictors of clinically significant biochemical recurrence and PSA kinetics after radical prostatectomy.
719607,Poster Session A: Prostate Cancer,An artificial intelligenceâ€“digital pathology algorithm to predict outcomes in a cohort of men diagnosed with prostate cancer within a low resource setting.
719608,Poster Session A: Prostate Cancer,Patient-derived primary prostate cancer epithelial cultures for studying prostate cancer cell evolution under hypoxia.
719609,Poster Session A: Prostate Cancer,PAM50 intrinsic subtyping and Decipher genomic classifier in biochemically recurrent prostate cancer after prostatectomy: Implications for ADT selection.
719610,Poster Session A: Prostate Cancer,Can clinico-genomic characterization reveal more aggressive prostate cancer among older patients with lower Gleason grade groups?
719611,Poster Session A: Prostate Cancer,Transcriptomic characterization of prostate cancer in patients with HIV infection.
719612,Poster Session A: Prostate Cancer,Spatially mapping the prostate cancer tumor microenvironment to reveal immune cell drivers of aggressive disease.
719613,Poster Session A: Prostate Cancer,Interaction between obesity and vitamin D and testosterone and vitamin D in prostate cancer patients on active surveillance in the PROVENT trial.
719614,Poster Session A: Prostate Cancer,Is there an opportunity for checkpoint inhibition in MYC amplified castration resistant prostate cancer?
719615,Poster Session A: Prostate Cancer,Integrating genomic prognostic and hallmark signatures from Decipher GRID to predict adverse outcomes in men on active surveillance for prostate cancer.
719616,Rapid Oral Abstract Session A: Prostate Cancer,Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer: First results of the PEACE-2 randomized phase III trial.
719617,Rapid Oral Abstract Session A: Prostate Cancer,External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial.
719618,Rapid Oral Abstract Session A: Prostate Cancer,"Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC)."
719619,Rapid Oral Abstract Session A: Prostate Cancer,First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study.
719620,Rapid Oral Abstract Session A: Prostate Cancer,Genomic alterations and pathologic responses to neoadjuvant androgen receptor pathway inhibitor (ARPI) doublets vs docetaxel triplets in the Genomic Umbrella Neoadjuvant study (GUNS).
719621,Rapid Oral Abstract Session A: Prostate Cancer,"Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) combined with ADT and ARPI in patients with PSMA-positive mHSPC."
719622,Oral Abstract Session B: Urothelial Carcinoma,"Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study."
719623,Oral Abstract Session B: Urothelial Carcinoma,RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
719624,Oral Abstract Session B: Urothelial Carcinoma,Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.
719625,Oral Abstract Session B: Urothelial Carcinoma,Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC): Integrated analysis of the RETAIN trials.
719626,Trials in Progress Poster Session B: Urothelial Carcinoma,Bladder cancer (BC) screening in un-affected Caucasian ancestry family members of patients who tested positive for germline homologous recombination repair (gHRR) and mismatch repair (gMMR) variants.
719627,Trials in Progress Poster Session B: Urothelial Carcinoma,Intismeran autogene (V940/mRNA-4157) plus bacillus Calmette-GuÃ©rin (BCG) versus BCG alone for high-risk nonâ€“muscle-invasive bladder cancer: The phase 2 INTerpath-011 study.
719628,Trials in Progress Poster Session B: Urothelial Carcinoma,ResQ133A-NMIBC: A phase 1/2 clinical trial of intravesical recombinant mycobacterium bacillus Calmette-Guerin (rBCG) in participants living with non-muscle invasive bladder cancer eligible to receive conventional BCG.
719629,Non-Muscle-Invasive Bladder Cancer Management in Transition: Integrating Emerging Evidence Into Practice,SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naÃ¯ve high-grade non-muscle invasive bladder cancer (NCT #03091660).
719630,Trials in Progress Poster Session B: Urothelial Carcinoma,A phase III randomised control clinical trial of radiotherapy with radiosensitisation versus intravesical bacillus Calmette-Guerin therapy for high-risk non-muscle invasive bladder cancer: TRAIN.
719631,Trials in Progress Poster Session B: Urothelial Carcinoma,EV-PRIME: Phase Ib/II study of enfortumab vedotin and pembrolizumab combined with radiotherapy as a bladder-sparing trimodality therapy in muscle invasive bladder cancer.
719632,Trials in Progress Poster Session B: Urothelial Carcinoma,Selective bladder preservation after neoadjuvant zanidatamab combined with tislelizumab and chemotherapy in patients with HER2-positive muscle-invasive bladder cancer (HARBOR): A multicenter study.
719633,Trials in Progress Poster Session B: Urothelial Carcinoma,The EMPOWER trial: Evaluating a home-based physical activity program (PAP) with the ExerciseRx digital platform vs. health education (HE) in people with non-muscle invasive bladder cancer (NMIBC).
719634,Trials in Progress Poster Session B: Urothelial Carcinoma,"IZABRIGHT-Bladder01: A randomized, open-label, phase 2/3 trial of izalontamab brengitecan (iza-bren; BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), vs platinum-based chemotherapy (PBC) for patients (pts) with advanced urothelial cancer (aUC) and disease progression on or after immunotherapy."
719635,Trials in Progress Poster Session B: Urothelial Carcinoma,TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy (CT) vs gemcitabine + platinum CT in participants with locally advanced or metastatic urothelial carcinoma (la/mUC) with progression on or after enfortumab vedotin (EV) + pembrolizumab (pembro).
719636,Trials in Progress Poster Session B: Urothelial Carcinoma,HCRN GU22-598: Phase 2 trial of enfortumab vedotin plus pembrolizumab with selective bladder sparing for treatment of muscle-invasive urothelial cancer of the bladder.
719637,Trials in Progress Poster Session B: Urothelial Carcinoma,A phase II trial of intravesical gemcitabine/docetaxel plus systemic pembrolizumab in high-risk nonâ€“muscle invasive bladder cancer unresponsive to BCG.
719638,Trials in Progress Poster Session B: Urothelial Carcinoma,Induction enfortumab vedotin plus pembrolizumab followed by maintenance pembrolizumab in first-line metastatic urothelial carcinoma (IMPROEV).
719639,Trials in Progress Poster Session B: Urothelial Carcinoma,A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937â€”Updated design.
719640,Trials in Progress Poster Session B: Urothelial Carcinoma,FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration.
719641,Trials in Progress Poster Session B: Urothelial Carcinoma,"CORE-008 cohort B: Evaluating intravesical cretostimogene grenadenorepvec in patients with high-risk, BCG-exposed non-muscle invasive bladder cancer."
719642,Trials in Progress Poster Session B: Urothelial Carcinoma,CAST-AI: Cystectomy after systemic therapy with ADC and immunotherapy.
719643,Trials in Progress Poster Session B: Urothelial Carcinoma,A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy.
719644,Trials in Progress Poster Session B: Urothelial Carcinoma,Rescuing cancer immunotherapy with plasma exchange in bladder cancer 1 (ReCIPE-B1).
719645,Trials in Progress Poster Session B: Urothelial Carcinoma,"A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302)."
719646,Trials in Progress Poster Session B: Urothelial Carcinoma,EMPOWER01: A phase II study of zanidatamab combined with bacillus Calmette-Guerin (BCG) in HER2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).
719647,Trials in Progress Poster Session B: Urothelial Carcinoma,A phase 2 study of gemcitabine plus carboplatin as second-line therapy after prior enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma.
719648,Trials in Progress Poster Session B: Urothelial Carcinoma,"[225Ac]Ac-AKY-1189, a Nectin-4 targeted radiopharmaceutical, in patients with previously treated locally advanced or metastatic solid tumors: Phase 1b Nectinium-2 study."
719649,Trials in Progress Poster Session B: Urothelial Carcinoma,"IMGeS study: A prospective, multicentre, phase II trial of sequential intravesical mitomycin-C and gemcitabine therapy in BCG-unresponsive high-risk NMIBC ineligible for or declining radical cystectomy."
719650,Trials in Progress Poster Session B: Urothelial Carcinoma,A phase II study evaluating the efficacy and safety of perioperative enfortumab vedotin plus toripalimab combined with endoscope-based kidney-sparing surgery for patients with high-risk upper tract urothelial carcinoma (WUTSUP-04-EV-JS001).
719651,Trials in Progress Poster Session B: Urothelial Carcinoma,"LUNAR: Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinomaâ€”A single-arm, open-label phase 1/2 trial."
719652,Trials in Progress Poster Session B: Urothelial Carcinoma,"RNDO-564-001: A first-in-human, phase 1/1b study of RNDO-564, a bispecific antibody for the treatment of advanced bladder cancer and other tumors associated with Nectin-4 expression."
719653,Trials in Progress Poster Session B: Urothelial Carcinoma,Circulating tumor DNA response adapted treatment de-escalation in metastatic urothelial carcinoma (CT-READ).
719654,Trials in Progress Poster Session B: Urothelial Carcinoma,SASAN-SPARING: A phase 2 trial of sasanlimab maintenance as bladder-sparing option after neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.
719655,Trials in Progress Poster Session B: Urothelial Carcinoma,Randomized trial of urinary tumor DNA (utDNA) testing-guided cystoscopy in high-risk/very high-risk non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB02.
719656,Trials in Progress Poster Session B: Urothelial Carcinoma,Randomized trial of urinary tumor DNA (utDNA) testing-guided repeat transurethral resection (re-TURBT) in non-muscle-invasive bladder cancer (NMIBC): TRUCE-LB01.
719657,Trials in Progress Poster Session B: Urothelial Carcinoma,The GAIN trial: Gemcitabine alternating with intravesical BCG randomized against BCG alone for patients with recurrent â€œBCG-exposedâ€ high-grade non-muscle invasive bladder cancer (NMIBC) (ALLIANCE A032303).
719658,Trials in Progress Poster Session B: Urothelial Carcinoma,Design and implementation of a patient-centric expanded access program with cretostimogene grenadenorepvec in non-muscle invasive bladder cancer unresponsive to bacillus Calmette-Guerin.
719659,Trials in Progress Poster Session B: Urothelial Carcinoma,SWOG 2427: Single arm phase II study of bladder preservation with immunoradiotherapy after a clinically meaningful response to neoadjuvant therapy in patients with muscle invasive bladder cancer (BRIGHT).
719660,Trials in Progress Poster Session B: Urothelial Carcinoma,"A phase 1/2, first-in-human study of AVZO-103, a bispecific Nectin4/Trop2 antibody-drug conjugate (ADC), as monotherapy and in combination therapy in patients with locally advanced or metastatic urothelial cancer (UC) or other solid tumors."
719661,Trials in Progress Poster Session B: Urothelial Carcinoma,CONSOLIDATE: A phase I/II study of radiotherapy combined with enfortumab vedotin (EV) for locally advanced bladder cancer with paired translational ctDNA and utDNA.
719662,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Tobacco use and survival among veterans with metastatic prostate cancer.
719663,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Determinants of treatment intensification in metastatic hormone-sensitive prostate cancer: Institutional vs patient-level factors in a diverse UK multicentre cohort.
719664,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical and cost impact of cabazitaxel versus lutetium-177 vipivotide tetraxetan (Lu-PSMA) for patients with metastatic castration-resistant prostate cancer (mCRPC).
719665,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Temporal and racial patterns in prostate cancer stage migration following USPSTF PSA screening policy changes: A SEER 2005â€“2022 analysis.
719666,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Representation of Latin American oncologists in oral sessions at the ASCO Genitourinary Cancers symposium: A five-year review (2021â€“2025).
719667,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Availability of clinical trials investigating prostate cancer (PC) in the United States (US).
719668,Poster Session B: Prostate Cancer and Urothelial Carcinoma,First-line (1L) systemic treatment patterns and impact of race in metastatic castration-resistant prostate cancer (mCRPC): A nationwide Veterans Affairs (VA) study.
719669,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Racial disparities and trends in the in-hospital mortality for malignant prostate cancer.
719670,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone.
719671,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world treatment transitions and healthcare resource utilization in patients with metastatic castration-resistant prostate cancer in Colombia.
719672,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Trends in advanced-stage prostate cancer over the last decade: Analysis from the National Cancer Database (NCDB).
719673,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.
719674,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of hospitalizations on health-related quality of life and overall survival in metastatic castration-sensitive prostate cancer: Insights from the ARANOTE trial.
719675,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Assistance of a large language modelâ€“based AI agent in preoperative communication for reduction of prostate cancer patients' anxiety and clinicians' burden: A prospective, randomized, single-blinded, phase II trial."
719676,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Cardiovascular risk evaluation in men with prostate cancer study (CARE-PC): Pilot study to assess patient awareness and risk mitigation.
719677,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Skeletal-related event impact on prostate cancer mortality in the older population in the US: A 24-year trend regression analysis.
719678,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Physician perspectives on the implementability of a cardiovascular risk score for prostate cancer: A PRISM-guided evaluation.
719679,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Improving quality of life measures for use in shared decision-making in advanced prostate cancer.
719680,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Non-cancer causes of death in patients with hormone-sensitive prostate cancer.
719681,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A rules-based AI triage system to identify NCCN-indicated genetic testing in prostate cancer: A performance analysis.
719682,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Quality improvement initiative to increase osteoporosis screening in patients with prostate cancer on long-term androgen deprivation therapy.
719683,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical characteristics and long-term outcomes of extreme responders to first line treatment of metastatic prostate cancer.
719684,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Imaging meets genomics in treatment-naÃ¯ve prostate cancer: SUVmax on prostate-specific membrane antigen (PSMA) PET as a biomarker of genomic classifier risk.
719685,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Trends in prostate cancer mortality after the 2012 USPSTF PSA guideline: Comparisons with kidney cancer and racial disparities.
719686,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prostate cancer in patients with HIV: A multisite retrospective cohort study.
719687,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Patterns and predictors of online cancer information seeking among urological cancer survivors.
719688,Poster Session B: Prostate Cancer and Urothelial Carcinoma,County-level educational attainment and long-term outcomes in older men with prostate cancer: A SEER-Medicare 2009â€“2017 study.
719689,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Assessing the impact of cardiovascular disease and ADT on survival disparities in prostate cancer.
719690,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of social environment on prostate cancer care across the clinical risk spectrum for Black men treated in community settings.
719691,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Urologist-level variation in androgen deprivation therapy intensification in patients with metastatic hormone-sensitive prostate cancer: A retrospective, population-based cohort study in Ontario, Canada."
719692,Poster Session B: Prostate Cancer and Urothelial Carcinoma,POSTER: Evaluating the impact of virtual peer-led support groups on prostate cancer survivorshipâ€”The AnCan experience.
719693,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of pre-visit educational videos on clinic efficiency for prostate cancer radiation oncology consultations.
719694,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Patterns of management and multidisciplinary care in high/very high and intermediate risk localized prostate cancer: A population-based study in Ontario, Canada."
719695,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Evaluating frailty and quality of life in low-income, uninsured men with prostate cancer."
719696,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Population-level trends in radiation treatment of low-risk prostate cancer.
719697,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Artificial intelligence (AI)â€“assisted eligibility screening for prostate cancer clinical trial matching.
719698,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Predictors of early termination in phase 2â€“3 genitourinary oncology trials: A two-decade analysis of clinicaltrials.gov.
719699,Poster Session B: Prostate Cancer and Urothelial Carcinoma,The nature of progression on active surveillance for grade group 2 prostate cancer.
719700,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Use of active surveillance in young men with low-risk prostate cancer.
719701,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of digital Ki67-based risk modeling on prognostic precision in nonâ€“muscle-invasive bladder cancer and high-risk subsets in mixed-grade tumors.
719702,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Multimodal integration of VI-RADS, radiomics, and deep learning features for prediction of pathology and prognosis in bladder cancer."
719703,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prostate cancer screening uptake and predictors of elevated prostate-specific antigen levels in Southwestern Nigeria.
719704,Poster Session B: Prostate Cancer and Urothelial Carcinoma,RNA based liquid biopsy testing of urine to predict pathological complete response to radiomolecular instillation NAC therapy before surgery: The Bladder BRIDGister experience.
719705,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Inferring optimal MTAP homozygous loss (homozygous deletion) detection in urothelial cancer: Prevalence and co-alterations based upon treatment exposure and anatomical location.
719706,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Comparing concordance of prostate cancer clinical trials and disease incidence in the United States in 2021 and 2022.
719707,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Inclusion of patients from Latin America in pivotal trials in genitourinary (GU) and cutaneous malignancies.
719708,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Patterns of neoadjuvant chemotherapy (NAC) use in stage II-III bladder cancer: A California Cancer Registry (CCR) analysis.
719709,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Temporal trends in mortality from bladder cancer with chronic kidney disease in the United States, 1999â€“2023: A population-based analysis."
719710,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Cost-effectiveness analysis of new perioperative treatment regimens for muscle-invasive bladder cancer in Germany.
719711,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prospective multicenter development and external validation of a narrow-band imaging based prediction model for malignancy risk in bladder lesions.
719712,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Healthcare utilization and expenditure burden in bladder cancer: A nationally representative analysis (MEPS 2015â€“2022).
719713,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Association of coexisting amyloidosis with survival outcomes in bladder cancer: A real-world cohort study.
719714,Poster Session B: Prostate Cancer and Urothelial Carcinoma,National trends and disparities in bladder cancer mortality associated with tobacco use between 1999 and 2020.
719715,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Demographic and socioeconomic disparities in early-onset vs. late-onset bladder cancer: A cross-sectional study in the NIH All of Us research program.
719716,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Regional variations in bladder cancer (BC) clinical trial availability within the United States (US).
719717,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Racial and ethnic disparities in variant histology bladder cancer: Insights from SEER 2000â€“2021.
719718,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Twenty-five years of bladder cancer mortality in the U.S. (1999â€“2024).
719719,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Any regression of tumor (ART) to discriminate improvement in overall survival (OS) in patients with metastatic urothelial carcinoma (mUC) receiving PD1/L1 inhibitors who exhibit stable disease (SD) by RECIST1.1.
719720,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical and social determinants of definitive surgical management in bladder cancer: A two-decade population-based analysis from the United States.
719721,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Addressing barriers to adopting first-line standards of care in la/mUC: A community practice-informed initiative.
719722,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Patient and trial design factors influencing participation in prospective bladder and kidney cancer clinical trials.
719723,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Characteristics, treatment (tx) patterns and outcomes in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC): A retrospective cohort study in England."
719724,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Consensus guidance on early identification and management of peripheral neuropathy in patients with UC receiving enfortumab vedotin: A Delphi study.
719725,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Structured step-based prehabilitation before radical cystectomy and its impact on postoperative recovery and perioperative burden: Interim analysis of the PRACTICE randomized trial (NCT06806059).
719726,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A national analysis of the impact of opioid use disorder on clinical outcomes in hospitalized patients with urothelial carcinoma.
719727,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world (rw) first-line (1L) treatment (tx) patterns and overall survival (OS) in patients (pts) with locally advanced/metastatic urothelial carcinoma (la/mUC) and frailty or comorbidities.
719728,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A real-world US community-based evaluation of recurrence among non-muscle-invasive bladder cancer patients treated with bacillus Calmette-GuÃ©rin.
719729,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Implementing evidence-based first-line therapy for metastatic urothelial carcinoma: A quality improvement initiative in community oncology.
719730,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Relevance of fresh frozen sections (FFS) for carcinoma in situ (CIS) detection in radical cystectomy for bladder cancer.
719731,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Enfortumab vedotin and pembrolizumab (EVP) outcomes in patients (pts) with advanced urothelial carcinoma (aUC) and FGFR3 alterations: UNITE study analysis.
719732,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Survival outcomes in metastatic bladder cancer patients in the United States.
719733,Poster Session B: Prostate Cancer and Urothelial Carcinoma,From bladder to upper urinary tract: Unveiling the epidemiological dynamics of urothelial carcinoma.
719734,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of neoadjuvant chemotherapy on outcomes of bladder-preserving chemoradiotherapy in muscle-invasive bladder cancer.
719735,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Treatment patterns and outcomes with second line (2L) therapies in patients (pts) with advanced urothelial carcinoma (aUC) previously treated with first line (1L) enfortumab vedotin (EV) with pembrolizumab (pembro).
719736,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Description and management strategies of prespecified treatment emergent adverse events (TEAEs) amongst patients (pts) treated with 1L enfortumab vedotin (EV) + pembrolizumab (P) for la/mUC in a real-world setting.
719737,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world neoadjuvant therapy utilization and outcomes in patients with muscle-invasive bladder cancer ineligible for cisplatin treatment.
719738,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world effectiveness and treatment patterns in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in Japan: Long term follow-up from the JAVEMACS chart review study.
719739,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Long-term effectiveness and safety of avelumab first-line maintenance (1LM) in locally advanced or metastatic urothelial carcinoma (la/mUC): Updated systematic literature review (SLR) and meta-analysis (MA).
719740,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Clinical burden of recurrence among older adults with muscle invasive bladder cancer undergoing tri-modal therapy in the real world: A SEER-Medicare, population-level study."
719741,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Opportunities for precision oncology: Real-world patterns and disparities in FGFR3 testing among US patients with advanced urothelial cancer.
719742,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world (rw) safety of first-line (1L) systemic regimens for locally advanced or metastatic urothelial cancer (la/mUC): Updated results from the ELEVATE UC-I study.
719743,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"FGFR-altered metastatic urothelial carcinoma in the real-world setting: Insight from the multicenter, prospective, non-interventional Italian registry of advanced/metastatic urothelial carcinoma (SATURNO)â€”A FICOG and Meet-URO study."
719744,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world overall survival (OS) improvements in metastatic urothelial carcinoma (mUC) across three key therapeutic eras.
719745,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical and genomic characteristics of advanced urothelial carcinoma (UC) patients (pts) who fail therapy with enfortumab vedodin (EV) plus pembrolizumab (P).
719746,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Retrospective analysis of treatment responses to enfortumab vedotin combined with pembrolizumab (EVP) based on FGFR2/3 alterations in patients (pts) with advanced urothelial carcinoma (aUC).
719747,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Neoadjuvant chemotherapy of node-positive M0 urothelial bladder cancer.
719748,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Assessing impact of RDI on outcomes in patients treated with enfortumab vedotin-pembrolizumab combination therapy.
719749,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world data on patientsâ€™ characteristics guiding physiciansâ€™ choice of first-line treatment for advanced urothelial carcinoma: Is there still a place for platinum-based chemotherapy?
719750,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Early relative dose intensity to predict survival outcomes in patients treated with enfortumab vedotin for metastatic urothelial carcinoma.
719751,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world use and effectiveness of first-line enfortumab vedotin (EV) with pembrolizumab (P) in patients with advanced urothelial carcinoma (aUC).
719752,Poster Session B: Prostate Cancer and Urothelial Carcinoma,End-of-life treatment patterns in patients with advanced urothelial carcinoma.
719753,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prognosis of patients (pts) with synchronous vs metachronous metastatic or locally advanced urothelial carcinoma (la/mUC).
719754,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world survival outcomes with single-agent erdafitinib (Erda) in patients (pts) with advanced urothelial carcinoma (aUC) based on line (L) of therapy and prior enfortumab vedotin (EV) treatment (Rx).
719755,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of neoadjuvant chemotherapy on perioperative outcomes following nephroureterectomy.
719756,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Disitamab vedotin plus PD-1 inhibitors as neoadjuvant therapy for cisplatin-ineligible muscle-invasive bladder cancer: A real-world retrospective study.
719757,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of upfront dose reductions on efficacy of enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC): A UNITE analysis.
719758,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Machine learning-based phenotyping and trial emulation to identify checkpoint inhibitor responders in advanced urothelial cancer.
719759,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Frequency and determinants of reproductive organ involvement in female patients undergoing radical cystectomy for bladder cancer.
719760,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.
719761,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world endpoints as surrogates for overall survival in metastatic bladder cancer.
719762,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Outcomes with subsequent therapies post-enfortumab vedotin/pembrolizumab (EVP) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
719763,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Oncological outcomes and HER2 expression of urothelial carcinoma with squamous differentiation: A retrospective study.
719764,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Predictive value of microsatellite instability/mismatch repair deficiency phenotype in upper tract urothelial carcinoma: A systematic review and meta-analysis.
719765,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Circulating tumor DNA kinetics as a biomarker of response to enfortumab-pembrolizumab in advanced urothelial carcinoma.
719766,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Front-line (1L) treatment and recurrence patterns among patients with high-risk nonâ€“muscle-invasive bladder cancer (HR-NMIBC) with papillary carcinoma (PAP) or carcinoma in situ (CIS) following bacillus Calmette-GuÃ©rin (BCG) or other intravesical therapies (IVT).
719767,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Quality of care (QoC) measures among patients with recurrent, papillary-only bacillus Calmette-GuÃ©rin (BCG)-experienced high-risk non-muscle invasive bladder cancer (HR-NMIBC)."
719768,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of prior immune checkpoint inhibitor (ICI) and interval from ICI exposure on outcomes with enfortumab vedotin and pembrolizumab (EVP) in advanced urothelial carcinoma (aUC).
719769,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world effectiveness and safety of enfortumab vedotin plus pembrolizumab versus gemcitabine-platinum chemotherapy in first-line treatment of advanced urothelial carcinoma: A propensity-matched analysis from the TriNetX global network.
719770,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real world outcomes comparing the use of GLP-1 agonists in patients with bladder cancer and comorbid obesity: A propensity score matched analysis from the Global Federated Health Research Network.
719771,Poster Session B: Prostate Cancer and Urothelial Carcinoma,OncoEducate: A pilot study of generative AI to support patient education in GU cancer care.
719772,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world time to next treatment in metastatic urothelial cancer patients: Enfortumab vedotin and pembrolizumab vs chemotherapy as first-line treatment.
719773,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Integrating pharmacists into uro-oncology care: Evaluation of patient satisfaction and well-being.
719774,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Incidence of immune-related adverse events (irAEs) and treatment discontinuation rates (TDR) in the adjuvant and metastatic setting in patients with urological malignancies: A systemic review and meta-analysis.
719775,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Correlation of adverse events (AEs) and clinical outcomes in first-line enfortumab vedotinâ€“pembrolizumab (EVP) treatment for locally advanced or metastatic urothelial cancer (La/mUC).
719776,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Bridging trial and practice: Real-world data of adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma.
719777,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Acute and chronic GU/GI toxicity after conventional versus hypofractionated radiotherapy (HFRT) with concurrent chemotherapy for muscle-invasive bladder cancer: A multi-institutional analysis by CURE-BC - Consortium for Urothelial Radiation Excellence â€“ Bladder Cancer.
719778,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Wearable device substudy of DISCUS: A randomised study comparing 3 vs 6 cycles of chemotherapy and sequenced avelumab in urothelial cancer.
719779,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Evaluation of quality of life endpoint planning and reporting in phase III genitourinary oncology randomized controlled trials.
719780,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Patient experiences with UGN-102 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC): Insights for shared decision making.
719781,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Implementation of patient reported outcomes as nonmuscle-invasive bladder cancer clinical trial endpoints.
719782,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Preoperative muscle quantity to predict acute kidney injury after radical cystectomy: A multicenter retrospective study.
719783,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical outcomes of metastatic urothelial carcinoma patients discontinuing enfortumab vedotin due to toxicity and/or clinical response.
719784,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Aligning goals of care at the time of treatment planning with the ABC123 framework: A pilot study.
719785,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Longitudinal assessment of patient-reported quality of life and mental health during active surveillance for low-grade NMIBC.
719786,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Characterizing frailty and its drivers in bladder cancer using machine learning-derived vulnerability and resource phenotypes.
719787,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Acute kidney injury to predict cardiovascular outcomes following radical cystectomy: A multicenter retrospective study.
719788,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Adjuvant vs switch-maintenance checkpoint inhibition in urothelial carcinoma: A systematic review and meta-analysis of randomized trials through July 2025.
719789,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in Part 1 of DESTINY-PanTumor02 (DP-02).
719790,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of FGFR3 alterations on first-line platinum based chemotherapy in patients with metastatic or locally advanced urothelial carcinoma: The retrospective IFUCA study.
719791,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Comparative outcomes of chemoradiotherapy regimens in muscle-invasive bladder cancer: A retrospective cohort study.
719792,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Does urinary diversion type influence long-term renal outcomes after radical cystectomy? A multicenter retrospective study.
719793,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Response to primary chemoablation with UGN-102 in different EOTRC risk groups.
719794,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.
719795,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Comparative treatment burden of BCG versus sequential gemcitabine and docetaxel for non-muscle-invasive bladder cancer: A time toxicity analysis.
719796,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effects of steroid pretreatment on adverse events and overall survival during enfortumab vedotin in urothelial carcinoma.
719797,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Trimodal therapy versus radical cystectomy in muscle-invasive bladder cancer: The overlooked influence of informative censoringâ€”A systematic review and meta-analysis.
719798,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical outcomes in patients with locally advanced or metastatic urothelial cancer (la/mUC) in France treated with avelumab first-line maintenance (1LM): A real-world observational study using the French National Healthcare Database (SystÃ¨me National des DonnÃ©es de SantÃ© [SNDS]).
719799,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Cystectomy-free survival following cretostimogene grenadenorepvec in high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ: Results from the phase 3 BOND-003 trial (Cohort C).
719800,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Enfortumab vedotin (EV) related cutaneous toxicity to predict metabolic response on fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan in advanced urothelial carcinoma (aUC): A single-center experience.
719801,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical outcomes of neoadjuvant chemotherapyâ€“guided bladder preservation in muscle-invasive bladder cancer: Long-term results of a phase II trial.
719802,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Sacituzumab tirumotecan (Sac-TMT) plus pembrolizumab (Pembro) in participants (Pts) with advanced urothelial carcinoma (UC): Results from phase 2 2870-002/SKB264-II-06 study.
719803,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Outcomes in participants (pts) with bacillus Calmette-GuÃ©rin (BCG)â€“unresponsive high-risk nonâ€“muscle-invasive bladder cancer (NMIBC) who underwent radical cystectomy (RC) after pembrolizumab (pembro): KEYNOTE-057 cohort A post hoc analysis.
719804,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Neoadjuvant (Neoadj) gemcitabine intravesical system (Gem-iDRS) plus cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for/refusing neoadj cisplatin-based chemotherapy (NAC): Updated perioperative outcomes from SunRISe-4.
719805,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"A provocative analysis of first-line strategies in advanced urothelial carcinoma: Reconstructed individual patient data comparisons of EVâ€“pembrolizumab, avelumab maintenance, and nivolumabâ€“cisplatinâ€“gemcitabine from their pivotal phase 3 trials."
719806,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer: The RAD VACCINE MIBC clinical trial.
719807,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Treatment of recurrent non-muscle invasive bladder cancer with UGN-301 (zalifrelimab) alone and in combination: A phase 1 dose escalation study.
719808,Poster Session B: Prostate Cancer and Urothelial Carcinoma,ADVANCED-2: Interim efficacy and safety data in BCG-unresponsive participants with high-grade non-muscle invasive bladder cancer.
719809,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical outcomes of pembrolizumab and enfortumab vedotin in variant histology urothelial carcinoma.
719810,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Topline results from BOND-003 cohort P: A multi-national, single-arm study of intravesical cretostimogene grenadenorepvec for treatment of high-risk, papillary only, BCG-unresponsive non-muscle invasive bladder cancer."
719811,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Characterization of patients (pts) responding to enfortumab vedotin plus pembrolizumab (EV+P): Exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
719812,Poster Session B: Prostate Cancer and Urothelial Carcinoma,ECOG ACRIN EA8192 cohort C: A phase II trial of neoadjuvant gemcitabine/durvalumab in patients (pts) with high grade (HG) upper tract urothelial carcinoma (UTUC) ineligible for cisplatin-based chemotherapy.
719813,Poster Session B: Prostate Cancer and Urothelial Carcinoma,First results from CORE-008 cohort A: Phase 2 study of intravesical cretostimogene grenadenorepvec in patients with high-risk BCG-naÃ¯ve non-muscle invasive bladder cancer.
719814,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Nivolumab and ipilimumab maintenance therapy for advanced or metastatic urothelial carcinoma: Final results from SOGUG-VEXILLUM trial.
719815,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Intravesical T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in BCG-naÃ¯ve high-risk NMIBC: A phase IIa trial."
719816,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical outcomes with immune checkpoint inhibitor and/or enfortumab vedotin in patients with MTAP-deleted metastatic urothelial carcinoma.
719817,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Neoadjuvant tislelizumab in combination with disitamab vedotin (RC48) followed by distal ureterectomy for patients with HER-2 expressing lower segment ureteral carcinoma (LSUC): A single-arm, phase II, single-center study."
719818,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with HER2-expressing muscle-invasive bladder cancer (MIBC) in the phase II RC48-C017 trial: Updated results.
719819,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A multicenter phase II study of first-line modified FOLFIRINOX in patients with advanced urachal cancer (ULTIMA; KCSG GU20-03).
719820,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Fixed low-dose nab-paclitaxel with tislelizumab in non-metastatic bladder cancer: A post-hoc analysis of dose expose in TRUCE-01 and TRUCE-02 trials.
719821,Poster Session B: Prostate Cancer and Urothelial Carcinoma,The impact of neoadjuvant chemotherapy relative dose intensity on pathological complete response and survival in muscle-invasive urothelial cancer: A multicentric retrospective study.
719822,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Association of renal function in non-hydronephrotic patients receiving PD-1 ICIs for bladder cancer with treatment response.
719823,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Concurrent use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients (pts) with advanced urothelial carcinoma (UC) receiving enfortumab vedotin (EV) plus pembrolizumab (P) therapy.
719824,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC): SURE-02 primary analysis and biomarker results."
719825,Poster Session B: Prostate Cancer and Urothelial Carcinoma,ETCTN 10483: Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following prior therapies for metastatic urothelial carcinoma (mUC) with FGFR3/2 genetic alterations (GAs).
719826,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical outcomes of neoadjuvant intravesical mitomycin-C therapy administered immediately prior to TURBT in NMIBC: Over three years of follow-up data from a randomized phase II trial.
719827,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Phase 1/2 study of an anti-PD-L1/IL-15 variant fusion protein (SIM0237) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC).
719828,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Interim safety and tolerability of TARA-002 in patients with BCG-naÃ¯ve and unresponsive high-grade non-muscle invasive bladder cancer in ADVANCED-2.
719829,Poster Session B: Prostate Cancer and Urothelial Carcinoma,The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
719830,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Safety and efficacy of platinum-based neoadjuvant chemotherapy with gemcitabine at 800 mg/m2 vs. 1000 mg/m2 in muscle-invasive bladder cancer: A multicenter retrospective study.
719831,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Neoadjuvant combined chemotherapy and immunotherapy for upper tract urothelial carcinoma: Final results from a phase II study.
719832,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of maximal transurethral resection before neoadjuvant chemotherapy on pathological response and survival in patients undergoing radical cystectomy for muscle-invasive bladder cancer: A multicenter retrospective study.
719833,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Efficacy and safety of disitamab vedotin combined with intravesical electromotive mitomycin-C in patients with HER2-expressing high-risk nonâ€“muscle-invasive bladder cancer: A phase II study.
719834,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of censorship in the interpretation of outcomes of the enfortumab vedotin plus pembrolizumab EV-302 phase 3 randomized clinical trial.
719835,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world comparative outcomes of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in metastatic urothelial carcinoma.
719836,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2â€“T4aN0M0 muscle-invasive bladder cancer.
719837,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Preliminary results from phase II enfortumab vedotin plus toripalimab compared to gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).
719838,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Optimizing docetaxel bladder penetration following gemcitabine pretreatment: An analysis of concentration and timing protocols.
719839,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): An IPD-based comparative analysis of KEYNOTE-905/EV-303 and PURE-01.
719840,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of HER2 IHC on enfortumab vedotin (EV) or EV+pembrolizumab (EVP) benefit in metastatic urothelial carcinoma.
719841,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Drug-releasing intravesical floating technology (DRIFT) for administration of sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer.
719842,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Genomic landscape of metastatic urothelial cancer in a multicenter Argentine cohort.
719843,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Transcriptomic deep learning approach for predicting chemotherapy response to cisplatin and gemcitabine in urothelial carcinoma.
719844,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Investigation of the natural killer (NK) cell axis in decoy-resistant IL18 treatment in bladder cancer (BCa).
719845,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"EGFR, HER2 alterations in advanced urothelial carcinoma (aUC): A retrospective analysis on survival outcomes."
719846,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Comprehensive plasma metabolomic profiling of metastatic urothelial carcinoma (mUC) pre- and post-immune checkpoint inhibitor (ICI) or platinum-based chemotherapy (PBC).
719847,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of HER2 expression and ERBB2 alterations on clinical outcomes in patients treated with enfortumab vedotin and pembrolizumab (EVP): UNITE study analysis.
719848,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of programmed cell death protein ligand 1 nuclear translocation mediated by Enolase on urothelial carcinoma immune evasion.
719849,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Association of HER2 and NECTIN4 expression with clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).
719850,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Inhibiting Î±2,6-sialylation and its association with nectin-4 stability and macropinocytic uptake in bladder cancer."
719851,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Early peripheral blood neutrophil/lymphocyte ratio (NLR) dynamics to predict primary refractory disease in metastatic urothelial carcinoma (mUC) patients receiving PD1/L1 inhibitors.
719852,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical utility of circulating tumor DNA profiling in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.
719853,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in muscle invasive bladder cancer.
719854,Poster Session B: Prostate Cancer and Urothelial Carcinoma,ERBB3-altered clinically advanced urothelial bladder cancer: Genomic landscape study and therapeutic possibilities.
719855,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Integrating genomic profiling and circulating tumor DNA monitoring to optimize surveillance strategies in muscle-invasive bladder cancer.
719856,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Membranous and cytoplasmic Nectin4 expression and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
719857,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Predictive value of early circulating tumor DNA (ctDNA) response in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin plus pembrolizumab (EVP).
719858,Poster Session B: Prostate Cancer and Urothelial Carcinoma,HER2 expression and genomic alterations in plasmacytoid urothelial carcinoma: Results from a large real-world institutional cohort.
719859,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prognostic and predictive impact of HER-2 expression in metastatic urothelial carcinoma: Results from the single-centre BLADDHER study.
719860,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical and genomic correlates of brain metastases in small cell carcinoma of the bladder.
719861,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Low-coverage whole-genome sequencing of urinary tumor DNA to characterize genomic correlates of lymphovascular invasion in bladder cancer.
719862,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Sasanlimab plus bacillus Calmette-GuÃ©rin in BCG-naive, high-risk nonâ€“muscle-invasive bladder cancer (NMIBC): Exploratory biomarker analysis of the phase 3 CREST trial."
719863,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Germline DNA repair gene (gDRG) variants in BCG un-responsive patients: A potential genetic implication for risk stratification and target therapy.
719864,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of tumor methionine metabolism via MAT2A on CD8âº T-cell exhaustion through SAM-CHOP axis in bladder cancer.
719865,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Proliferation- and immune-informed fusion of multiscale image features for bladder cancer prognosis.
719866,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Mechanistic insights into bacillus Calmette-GuÃ©rin (BCG) sensitivity in non-muscle invasive bladder cancer (NMIBC) with ERCC2 alterations.
719867,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Dissecting the tumor microenvironment of advanced urothelial carcinoma pre and post enfortumab vedotin Â± pembrolizumab: A single-cell spatial transcriptomic analysis.
719868,Poster Session B: Prostate Cancer and Urothelial Carcinoma,ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial.
719869,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of tumor mutational burden on clinical outcomes in muscle-invasive bladder cancer patients treated with neoadjuvant chemotherapy.
719870,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: A subgroup analysis of the phase II POLARIS-03 trial.
719871,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Detecting MTAP loss in liquid biopsies from patients (pts) with clinically advanced urothelial bladder cancer (CAUBC).
719872,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Metaproteomics based subtypes in muscle invasive bladder carcinoma and association with survival.
719873,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Prospective, blinded validation of a urinary cfDNA methylation assay in bladder cancer."
719874,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Integrating circulating tumor DNA (ctDNA) and TP53 alteration variant allele frequency (VAF) to predict outcomes in advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV).
719875,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of loss of KDM6A-mediated genomic instability and metabolic reprogramming on response to therapeutic perturbations in bladder cancer.
719876,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Ultra-sensitive molecular residual disease detection via tumor-informed whole-genome sequencing-based ctDNA assay in resectable urothelial cancer in the MONSTAR-SCREEN-3 project.
719877,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Immune senescence and antigen presentation defects in BCG-unresponsive bladder cancer.
719878,Poster Session B: Prostate Cancer and Urothelial Carcinoma,ADC target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy.
719879,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Circulating tumor cell detection and prognostic relevance in patients with metastatic genitourinary cancers.
719880,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Toward noninvasive genomic profiling in muscle-invasive bladder cancer using quantitative CT texture analysis.
719881,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Clinical utility of a urinary DNA methylation biomarker test in the diagnosis and surveillance of upper tract urothelial carcinoma: Results from a prospective trial.
719882,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Homologous recombination repair gene alterations and outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
719883,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Multidimensional profiling of clinical trial cohorts and the characterization of radiotherapy/immunotherapy response biology in localised and metastatic muscle-invasive bladder cancer.
719884,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Next-generation sequencing of bladder and upper tract micropapillary variant urothelial carcinoma patients and associated clinical outcomes.
719885,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Association of ctDNA status with upstaging, pathologic outcomes, and genomic alterations in high-risk NMIBC."
719886,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Biomarker analysis of neoadjuvant atezolizumab in upper-tract urothelial carcinoma: Results from the ABACUS-2 trial.
719887,Poster Session B: Prostate Cancer and Urothelial Carcinoma,HER2 and Nectin-4 IHC expression and clinical outcomes with enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.
719888,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Detecting FGFR3 genomic alterations in liquid biopsies from patients with clinically advanced urothelial bladder cancer.
719889,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Tumor mutational burden to predict overall survival independent of TP53 status in TCGA bladder cancer cohort.
719890,Poster Session B: Prostate Cancer and Urothelial Carcinoma,The overlooked culprit: Tumor size in muscle-invasive bladder cancer.
719891,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prognostic utility of tumor mutational burden in older adults (â‰¥75 years) with bladder cancer: A TCGA geriatric oncology analysis.
719892,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Duplex-Seq derived urinary cell-free DNA of Lynch syndrome patients with upper tract urothelial carcinoma.
719893,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Ferroptosis suppression and its association with chemoradiotherapy resistance in muscle-invasive bladder cancer.
719894,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A composite biomarker approach to withhold neoadjuvant chemotherapy in select muscle-invasive bladder cancer patients.
719895,Poster Session B: Prostate Cancer and Urothelial Carcinoma,The molecular mechanism of lymph node metastasis driven by B lymphocyte FOXO1 palmitoylation induced by ACSL5 deficiency in bladder cancer cells.
719896,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A binary dual-stain immunohistochemistry classifier to predict pathologic downstaging after neoadjuvant chemotherapy in muscle-invasive bladder cancer.
719897,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Liquid biopsy-based detection of MTAP gene loss in non-muscle invasive bladder cancer.
719898,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Comprehensive multi-layered omics analysis of the UBC landscape for precision medicine and its clinical implications: From deciphering distinct molecular heterogeneity to guiding treatment decision-making and developing tailored therapeutic strategies.
719899,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Circulating tumor DNA analysis from the prospective pT0 study of systematic endoscopic evaluation in patients undergoing radical cystectomy for bladder cancer.
719900,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Blood- and urine-based ctDNA profiling and monitoring in bladder carcinoma in situ.
719901,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Real-world urinary detection of FGFR alterations to guide FGFR inhibitor therapy in bladder cancer.
719902,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Blood and urine liquid biopsy for molecular monitoring in HER2-positive muscle-invasive bladder cancer under bladder-preserving therapy.
719903,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Hemoglobin, albumin, lymphocyte, and platelet (HALP) score as a prognostic indicator in patients with bladder cancer undergoing radical cystectomy."
719904,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Homologous recombination deficiency signature (HRDsig) in adenocarcinoma of the bladder (ACB): Implications for PARP inhibitor (PARPi) treatment.
719905,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Association of non-luminal subtype with overall survival in high-risk non-muscle invasive bladder cancer patients: Biomarker results from the Bladder Cancer Prognosis Programme.
719906,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Association between non-luminal molecular subtypes and complete response rates after neoadjuvant chemo-immune therapy for muscle-invasive bladder cancer: Biomarker analyses of NURE-combo and BLASST-01 phase 2 clinical trials.
719907,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Membranous Nectin-4 expression to predict enfortumab vedotin response in metastatic urothelial carcinoma.
719908,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Liquid biopsy guided disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer (DECIDING-I study).
719909,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Bladder cancer innervation: Does it affect prognosis?
719910,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Examining the impact of TGF-ÃŸ activity on fibroblast infiltration and immune exclusion in MIBC.
719911,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Development of a non-muscle invasive bladder cancer (NMIBC) genomic score (NGS) to predict early BCG failure.
719912,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Multi-omic remodeling of urine-exposed ileal mucosa after ileocystoplasty.
719913,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Preoperative CT radiomicsâ€“deep learning signature for lymphovascular invasion in bladder cancer: External validation and clinical utility.
719914,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Genomic heterogeneity in urothelial carcinoma with trophoblastic differentiation: Real world data.
719915,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Genomic characterization of upper tract urothelial carcinoma (UTUC) with or without sarcomatoid differentiation.
719916,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Clinical, radiographic, and genomic predictors of response to neoadjuvant chemotherapy for high-risk localized upper tract urothelial carcinoma."
719917,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Autoantibody (AAb) profiling in metastatic cisplatin-ineligible metastatic urothelial carcinoma (mUC) treated with ipilimumab (IPI), nivolumab (NIVO), and sacituzumab govitecan (SG)."
719918,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Prognostic significance of the preoperative De Ritis ratio and its association with sarcopenia in muscle-invasive bladder cancer: A multicenter retrospective study.
719919,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Circulating tumor DNA dynamics as a predictive biomarker of response and survival in metastatic urothelial carcinoma treated with enfortumab vedotin and pembrolizumab.
719920,Poster Session B: Prostate Cancer and Urothelial Carcinoma,"Artificial intelligence in the diagnosis and prognosis of upper tract urothelial carcinoma: A comprehensive review of current evidence, methodological standards, and future directions."
719921,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Family awareness of genetic risk in affected Caucasian ancestry members with bladder cancer (BC) associated with germline variants in DNAâ€repair genes (gDRGs).
719922,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Fostering inclusive language for genitourinary cancer research: A multi-stakeholder co-creation effort.
719923,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Histopathologic and spatial transcriptomic analyses of en bloc resections of de novo and recurrent bladder tumors.
719924,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Association of urothelial carcinoma with squamous differentiation with Nectin-4 expression and outcomes with enfortumab vedotin (EV) treatment.
719925,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Comparison of clinicopathological features and prognoses of de-novo metastatic male and female bladder cancer patients.
719926,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Impact of positive ureteral margin on upper tract recurrence after radical cystectomy for bladder cancer.
719927,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Whole genomeâ€“based ultrasensitive circulating tumor DNA clearance as a biomarker of exceptional outcomes with enfortumab vedotin and pembrolizumab in urothelial carcinoma: Preliminary real-world results.
719928,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Healthcare resource utilization (HCRU) and costs among US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with first-line (1L) treatment regimens: Results from the ELEVATE UC-I study.
719929,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Effect of epidural analgesia vs. combined intravenous patient-controlled analgesia and transversus abdominis plane block on postoperative outcomes after radical cystectomy.
719930,Poster Session B: Prostate Cancer and Urothelial Carcinoma,A novel large language model framework for automated extraction of pathology data in radical cystectomy.
719931,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Antibody-drug conjugates in genitourinary malignancies: The clinical trial landscape and emerging efficacy benchmarks.
719932,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Inpatient outcomes of bladder cancer: Racial and socioeconomic disparities in a nationally representative sample (2020-2022).
719933,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Quantifying the value of tumor response and survival: Perceived monetary loss in anticancer therapy.
719934,Multidisciplinary Tumor Board: Innovative Approaches to Bladder Preservation,Induction ipilimumab plus nivolumab followed by consolidating chemoradiotherapy as bladder-sparing treatment in stage II/III urothelial carcinoma of the bladder: The phase 2 Indi-Blade trial.
719935,Rapid Oral Abstract Session B: Urothelial Carcinoma,KEYMAKER-U04 substudy 04B: First-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).
719936,Rapid Oral Abstract Session B: Urothelial Carcinoma,Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results.
719937,Rapid Oral Abstract Session B: Urothelial Carcinoma,Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.
719938,Rapid Oral Abstract Session B: Urothelial Carcinoma,Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC; HCRN GU 20-444).
719939,Rapid Oral Abstract Session B: Urothelial Carcinoma,"Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts) with advanced urothelial carcinoma (adv UC)."
719940,Poster Session B: Prostate Cancer and Urothelial Carcinoma,Does time to recurrence after radical cystectomy for bladder cancer impact subsequent survival?
719941,Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after antiâ€“PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.
719942,Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Patient-reported outcomes in resected renal cell carcinoma: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.
719943,Rapid Oral Abstract Session B: Urothelial Carcinoma,Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.
719944,Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,"Initial results from CLIMATE, a prospective cohort study assessing the clinical utility of miR-371a-3p (miR-371) as a marker of minimal residual disease (MRD) in clinical stage 1 testicular germ cell tumour (TGCT): ANZUP 1906."
719945,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Impact of treatment approaches on survival in bulky node-positive penile squamous cell carcinoma: A National Cancer Database analysis.
719946,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Educational representation of genitourinary malignancies in medical student curricula: A cross-sectional review of oncologic education in Caribbean and South American schools.
719947,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Unveiling the rare: p16 expression and real-world management of penile cancer in Boliviaâ€”Insights from a country with high HPV and penile cancer prevalence.
719948,Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.
719949,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world outcomes of systemic therapy in penile cancer: A single-center experience from a tertiary referral hospital in Mexico.
719950,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Single-cell transcriptomic characterization of NECTIN-4 expression in penile squamous cell carcinoma.
719951,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Comparative outcomes of radiotherapy and interventional therapy for adrenal oligometastases: A multicenter retrospective study.
719952,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Multi-hit PIK3CA mutations in clinically advanced (CA) penile squamous cell carcinoma (penSCC): A genomic landscape study.
719953,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",MTAP loss in penile squamous cell carcinoma (penSCC): A genomic landscape study.
719954,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (MeetUro 31): Preliminary analysis of radiomics featuresâ€”A Meet-URO and AIRC study (NCT05782400).
719955,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Spatial and molecular determinants of response in penile squamous cell carcinoma.
719956,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",End-of-life care preferences in penile cancer patients: Shifting patterns and disparities over two decades.
719957,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",The prognostic role of PD-L1 in penile squamous cell carcinoma: A systematic review and meta-analysis.
719958,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",The application of 5.0-Tesla non-enhanced MRI in the preoperative assessment of renal tumors.
719959,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",External validation of AI age discrepancy as a measure of frailty in kidney tumor patients.
719960,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Improving access to clinical trial participation among underrepresented kidney cancer patients.
719961,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Comparison of outcomes of contemporary immune-check point inhibitors combinations in Black patients versus White patients with metastatic renal cell carcinoma (mRCC).
719962,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Predicting clear cell subtype for kidney tumors from cross-sectional imaging using artificial intelligence.
719963,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Prediction of socioeconomic disadvantage using AI analysis of CT imaging in kidney cancer patients.
719964,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Palliative care utilization and hospitalization outcomes among patients with renal cell carcinoma: A 2020-2022 National Inpatient Sample analysis.
719965,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Postoperative surveillance in non clear cell renal cancer: Is current practice best practice?
719966,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Trends in renal cell carcinoma mortality associated with tobacco use in U.S. adults aged â‰¥45 years, 1999â€“2023: A population-based CDC WONDER analysis."
719967,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Second-line therapy after ipilimumab and nivolumab in advanced renal cell carcinoma: A multicenter real-world study (GUARDIANS).
719968,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Geographic disparities in the availability of renal cell carcinoma (RCC) clinical trials in the United States (US).
719969,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Deferred cytoreductive nephrectomy in patients with advanced RCC treated with first-line nivolumab plus ipilimumab: A propensity score-matched analysis from the RENOIR study (KCSG GU22-13).
719970,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world effectiveness and safety of first-line (1L) avelumab + axitinib (ave + axi) in patients with advanced renal cell carcinoma (aRCC): Final analysis of the prospective AVION study.
719971,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma.
719972,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Patient and physician preferences for treatment in advanced renal cell carcinoma (PEAR): An international, multi-centre discrete choice experiment (DCE)."
719973,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",A multi-institution analysis of outcomes with first-line ipilimumab and nivolumab for 514 patients with metastatic clear cell renal cell carcinoma by number of doses.
719974,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Treatment (Rx) patterns and outcomes with second-line (2L) therapy in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with cabozantinib plus nivolumab (cabo+nivo) or lenvatinib plus pembrolizumab (len+pem) in first-line (1L).
719975,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Serum IgG: A novel biomarker for efficacy and prognosis in metastatic clear cell renal cell carcinoma patients receiving first-line immunotherapy combined with tyrosine kinase inhibitors.
719976,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Differential performance of immune-combinations (ICI-ICI vs ICI-TKI) in metastatic renal cell carcinoma (mRCC) with sarcomatoid features (sRCC) (Meet-URO 33 analysis).
719977,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",A retrospective evaluation of treatment patterns following cabozantinib treatment for advanced renal cancer: The CABONEXT study.
719978,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Intratumoral mature TLSs to predict response to ICI rechallenge in nonâ€“clear cell renal cell carcinoma.
719979,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world efficacy of nivolumab plus cabozantinib in metastatic renal cell carcinoma (mRCC) using the IMDC.
719980,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Clinical outcomes and tolerability of ipilimumab/nivolumab in older (â‰¥70 years) versus younger patients with metastatic clear cell RCC: A multi-institutional analysis of 514 patients.
719981,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world analysis of renal cell carcinoma with sarcomatoid differentiation treated with first-line immunotherapy combinations: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
719982,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Optimal hour of immune checkpoint inhibitors (ICIs) administration in metastatic renal cell carcinoma (mRCC): The â€œTic-Tacâ€ study.
719983,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Sarcomatoid versus rhabdoid dedifferentiation and histologic grade-specific outcomes in metastatic clear cell renal cell carcinoma (mccRCC): A multi-institutional analysis of 514 patients.
719984,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Prognostic value of neutrophil-to-eosinophil ratio (NER) in patients with metastatic renal-cell carcinoma treated with immunotherapy.
719985,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Impact of age on outcomes in metastatic nonâ€“clear cell renal cell carcinoma (mnccRCC): A real-world TriNetX analysis.
719986,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Partial nephrectomy (PN) versus ablative therapies (AT) for T1a clear cell renal cell carcinoma (ccRCC): Analysis of 2,161 patients."
719987,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Outcomes of nephrectomy in patients with pathologic complete response to immune checkpoint inhibitor therapy for renal cell carcinoma: A multicenter study.
719988,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Extended multi-centre review of adjuvant pembrolizumab for renal cell carcinoma.
719989,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Associations of DNA damage repair (DDR) pathway class and allelic configuration with survival in metastatic renal cell carcinoma.
719990,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world comparative effectiveness of first-line (1L) cabozantinib (C) versus cabozantinib with nivolumab (C+N) in patients (pts) with metastatic papillary renal cell carcinoma (mPRCC).
719991,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Outcomes of delayed cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitor therapy.
719992,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Treatment patterns, attrition, and survival outcomes in patients with metastatic unclassified renal cell carcinoma."
719993,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Chromophobe renal cell carcinoma: Long-term survival and treatment patterns from a real-world cohort.
719994,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Clinical efficacy of belzutifan in pre-treated renal cell carcinoma: A real world retrospective cohort benchmarked to LITESPARK-005.
719995,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Perioperative outcomes of open versus robot-assisted radical nephrectomy with IVC thrombectomy.
719996,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Contemporary outcomes of nephrectomy with IVC thrombectomy: Analysis from a large multi-institutional database.
719997,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Optimal duration of immune checkpoint inhibitor therapy in genitourinary cancers: A systematic review and meta-analysis of real-world studies.
719998,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data from the Canadian Kidney Cancer Information System (CKCis) database.
719999,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Metastatic progression and toxicity in high-risk clear cell renal cell carcinoma patients treated with adjuvant pembrolizumab at a tertiary care center.
720000,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",End-of-life treatment patterns in patients (pts) with metastatic renal cell carcinoma (mRCC).
720001,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Treatment (Rx) patterns and survival outcomes in patients with metastatic chromophobe renal cell carcinoma (mchRCC).
720002,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Adjuvant pembrolizumab in nonâ€“clear cell renal cell carcinoma after nephrectomy: An international multicenter study.
720003,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world outcomes of clear-cell renal cell carcinoma (ccRCC) patients treated with belzutifan stratified by von Hippel-Lindau (VHL) status.
720004,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world early quality of life (QOL) changes on IO-based regimens in the prospective observational ODYSSEY metastatic renal cell carcinoma (mRCC) study.
720005,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Clinical outcomes of retroperitoneal lymph node dissection in patients with cT3â€“4 Nx M0 nonâ€“clear cell renal cell carcinoma.
720006,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Efficacy and safety of belzutifan in patients with metastatic clear cell renal cell carcinoma (mccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
720007,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world effects of sodium-glucose cotransporter 2 inhibitor use on renal cell carcinoma.
720008,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Treatment utilization in metastatic renal cell carcinoma (mRCC) following implementation of a national cancer drug list (CDL) drug reimbursement program in Singapore: A real-world single-centre study.
720009,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Trends in overall survival with evolving systemic therapies for metastatic nonâ€“clear cell RCC: An analysis over two decades.
720010,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Immune checkpoint inhibitor combinations in sarcomatoid metastatic clear cell renal cell carcinoma: A systematic review and meta-analysis.
720011,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real-world efficacy and safety of tivozanib in metastatic renal cell carcinoma in a diverse cohort: A multicenter study from the City of Hope enterprise.
720012,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Real world outcomes comparing the use of GLP-1 agonists in patients with renal cell carcinoma (RCC) and comorbid obesity: A propensity score matched analysis from Global Federated Health Research Network.
720013,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Discrepancies in the administration of sequential therapies for metastatic renal cell carcinoma: Real-world practice versus randomized controlled trials.
720014,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Diabetic retinopathy as a marker for renal cell carcinoma among patients with type 2 diabetes mellitus.
720015,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Bleeding risk with concurrent anticoagulation and VEGF-TKI therapy in mRCC: A real-world TriNetX analysis.
720016,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Effect of remote exercise on fatigue and quality of life (QOL) across genitourinary (GU) cancer types.
720017,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Efficacy of subsequent therapy in patients with metastatic renal cell carcinoma of intermediate and poor risk following first-line immuno-oncology combinations.
720018,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Emotional concerns due to kidney cancer (KC) and disparities in patient support across North America (NA): Results from the International Kidney Cancer Coalition (IKCC) global patient survey (GPS).
720019,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2Î± inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20."
720020,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Phase 2 trial of belzutifan in participants from China and Japan with von Hippel-Lindau disease-associated tumors: Results from LITESPARK-015 cohort B1.
720021,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","A phase II trial of nivolumab, ipilimumab and cabozantinib in patients with brain metastases from renal cell carcinoma."
720022,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Guarding the kidneys in the immunotherapy era: Pooled incidence and severity of immune-related nephritis in renal-cell carcinoma treated with PD-1/PD-L1â€“based regimens.
720023,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Response of venous tumor thrombi in renal cell carcinoma to immune checkpoint inhibitor therapy: A multicenter retrospective cohort study.
720024,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Fruquintinib combined with everolimus in Chinese patients with advanced/metastatic clear cell renal cell carcinoma (ccRCC) after progression on immune checkpoint inhibitors (ICIs): Results from a phase II single arm clinical trial.
720025,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Metastasis-directed therapy with or without pembrolizumab for oligometastatic clear cell renal cell carcinoma: Pooled analysis of two prospective single-arm phase II trials.
720026,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Incidence of symptomatic hypoxia in a high-altitude cohort of patients with renal cell carcinoma (RCC) treated with belzutifan.
720027,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Interim analysis of vorolanib combined with cadonilimab in previously untreated patients with advanced renal cell carcinoma.
720028,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Efficacy of selective renal tumor embolization combined with axitinib and reduced-dose toripalimab in oligometastatic clear cell renal carcinoma: An updated analysis with patient-derived organoid and immune co-culture insights.
720029,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Pan-cancer assessment of deletions in COQ biosynthesis pathway genes associated with poor prognosis and potential benefit from BPM31510 intervention in kidney cancers.
720030,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",First results of a dose-escalation study evaluating Clostridium butyricum MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).
720031,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Network meta-analysis of second- and later-line therapies in advanced renal cell carcinoma: A comparative effectiveness approach.
720032,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Long-term clinical outcomes with Clostridium butyricum MIYAIRI 588 (CBM588) and TOPOSCORE assessment in patients receiving immune checkpoint inhibitor (ICI)-based combinations for metastatic renal cell carcinoma (mRCC).
720033,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","A prospective, multi-center, phase Ib/II trial of first-line cadonilimab plus axitinib in advanced non-clear cell renal cell carcinoma."
720034,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Characterization of depth and durability of response in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) who received cabozantinib plus nivolumab (C+N): Long-term follow-up and exploratory analysis of CheckMate 9ER.
720035,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma and venous tumor thrombus: Results from the first analysis of the PELET trial.
720036,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Cadonilimab plus lenvatinib in advanced renal cell carcinoma: Interim analysis of a prospective, multi-cohort phase II study."
720037,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Long-term efficacy and patient experience with neoadjuvant cabozantinib for locally advanced renal cell carcinoma.
720038,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",KEYMAKER-U03 substudy 03B: Novel investigative regimens for previously treated advanced clear cell renal cell carcinoma (ccRCC).
720039,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",V-set immunoregulatory receptor as a novel molecular target for genitourinary cancers.
720040,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Use of spatial transcriptomics to analyze the molecular landscape of tuberous sclerosis complexâ€“associated angiomyolipoma: Implications for diagnosis and therapeutic targeting.
720041,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",A novel cabozantinib formulation with reduced pharmacokinetic variability and the potential to improve safety in patients with renal cell carcinoma.
720042,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Promoter methylation of aquaporin 1 as a prognostic biomarker in clear cell renal cell carcinoma.
720043,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",PARP1 and BRCA1/2 expression and overall survival in high risk of recurrence localized clear cell-type renal cell carcinoma.
720044,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Pattern of disease recurrence and outcomes of localized high-risk renal cell carcinoma (RCC) patients treated with adjuvant (adj) immunotherapy: A single center experience.
720045,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Genome-wide association to identify SNPs associated with severe adverse events and clinical outcomes in advanced renal cell carcinoma treated with nivolumab.
720046,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).
720047,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Association of prior 5-Î±-reductase inhibitor exposure with ICI benefit in metastatic RCC: Multicentre cohort with single-cell immune profiling.
720048,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Use of ultra-sensitive whole genome circulating tumor DNA detection to predict early recurrence in high-risk localized RCC after nephrectomy: Preliminary real-world findings.
720049,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Integrative genomic landscape of germline exome alterations in renal cell carcinoma, unclassified with medullary phenotype."
720050,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Unveiling sex-based disparities in advanced renal cell carcinoma: Insights from the real-world Meet-URO33 (REGAL) study.
720051,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Pathologic findings and clinical outcomes after immune checkpoint blockade in renal cell carcinoma patients undergoing deferred consolidative nephrectomy.
720052,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Utility of circulating tumor DNA in patients with renal cell carcinoma at increased risk of recurrence after resection.
720053,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Peripheral blood correlates of outcomes with adjuvant tremelimumab plus durvalumab for patients with renal cell carcinoma at high or intermediate risk of relapse: Initial results from the TransRAMPART study.
720054,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Genomic and clinical correlates of belzutifan treatment in renal cell carcinoma (RCC): A retrospective analysis of 240 RCC patients.
720055,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",MTAP loss in sarcomatoid renal cell carcinoma (srcRCC): A genomic landscape study.
720056,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Metabolic reprogramming in chromophobe renal cell carcinoma: Transcriptomic insights into the transition from indolent to aggressive disease.
720057,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Association of enriched YES1 tumor expression at the stromal interface with overall survival in clear cell renal cell carcinoma when treated with first-line immune checkpoint blockade.
720058,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Use of genomic dedifferentiation signature to predict clinical outcomes with doublet vs triplet therapy in the phase III COSMIC-313 trial.
720059,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",VHL wild-type clinically advanced clear cell renal cell carcinoma (ccRCC): A genomic landscape study.
720060,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Association of pre-operative circulating tumor DNA (ctDNA) status with clinicopathologic characteristics in patients (pts) with localized renal cell carcinoma (RCC).
720061,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Circulating kidney injury marker-1 (KIM-1) in metastatic renal cell carcinoma with divergent histologies (RCCdh): Biomarker analysis of the CAN-I trial.
720062,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Kidney injury moleculeâ€1 (KIM-1) in localized and metastatic renal cell carcinoma (RCC): A meta-analysis and systematic review.
720063,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Pilot phase I trial of an implantable microdevice for in vivo evaluation of drug response in renal cell carcinoma.
720064,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Circulating tumor DNA (ctDNA) analysis in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC) treated with first-line pembrolizumab (pembro) monotherapy from the phase 2 KEYNOTE-427 study.
720065,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Correlation without causality between BAP1 loss and the metastasis-associated miR-183/96/182 cluster expression in renal cell carcinoma.
720066,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Molecular and clinical correlates of early-onset clear cell renal cell carcinoma (eoRCC): A real-world multi-omics analysis.
720067,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Immunological clustering from peripheral blood to define prognosis and T cell exhaustion profiles in renal cell carcinoma.
720068,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Association of serum kidney injury molecule-1 with treatment response and survival in metastatic renal cell carcinoma.
720069,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Features of early and late recurrence versus de novo metastatic ccRCC: Findings from JAVELIN Renal 101.
720070,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Biomarker analysis from the phase 2 LITESPARK-013 study of 2 different belzutifan (bel) doses in participants (pts) with advanced clear cell renal cell carcinoma (ccRCC).
720071,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Development and validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in renal cell carcinoma.
720072,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Effect of tryptophanâ€“serotoninâ€“kynurenine pathways on immune landscape and survival in clear cell renal cell carcinoma: TCGA-KIRC transcriptomic analysis.
720073,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Analysis of CA9 and PSMA expression in clear cell renal cell carcinoma (ccRCC) and the effect of prior therapies.
720074,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Expansion and characterization of tumor-infiltrating lymphocytes from primary and metastatic immune checkpoint inhibitor-exposed renal cell carcinoma tumors.
720075,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Germline platelet polygenic risk score to predict renal cell carcinoma survival via sustained thrombocytosis.
720076,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Circulating angiogenicâ€“myeloid cytokine axis to predict benefit from first-line immune-checkpoint inhibitor combinations in metastatic clear cell renal cell carcinoma.
720077,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Pathologic response after neoadjuvant therapy in renal cell carcinoma using irRVT criteria.
720078,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Single-cell transcriptomic investigation of the cell-of-origin and oncogenic pathways across variant histologies of renal cell carcinoma.
720079,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Baseline and longitudinal body composition profile association with immune-checkpoint inhibitor (ICI) outcomes in metastatic clear-cell renal cell carcinoma (mccRCC).
720080,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Correlation of mutated B2M, an immune-related gene, with overall survival in renal cell carcinoma."
720081,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Prevalence and clinical impact of actionable genomic alterations in nonâ€“clear cell renal cell carcinoma: A review of NGS-based trials and real-world data.
720082,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",KIM-1 levels in papillary renal cell carcinoma from the CALYPSO trial.
720083,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Succinate dehydrogenase B deficient renal cell carcinoma (RCC): A genomic landscape study.
720084,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Predictors and clinical outcomes of renal tumor upstaging from cT1 to pT3a disease in patients who underwent robot-assisted partial nephrectomy.
720085,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Association of SETD2 mutation with prognostic features and susceptibility to acute kidney injury in renal cell carcinoma.
720086,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Efficacy and safety of avelumab + axitinib vs sunitinib in patients (pts) with very favorable-risk advanced renal cell carcinoma (aRCC): Subgroup analysis from the JAVELIN Renal 101 trial.
720087,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Healthy donor fecal microbiota transplantation combined with immunotherapy in metastatic renal cell carcinoma: Results from the phase I PERFORM trial.
720088,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Early monitoring of derived neutrophil-to-lymphocyte ratio (dNLR) as a predictive biomarker of benefit to immune checkpoint inhibitors (ICI) in advanced clear cell renal cell carcinoma (ccRCC).
720089,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Clinical significance of baseline serum IgG in metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy.
720090,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Evaluating the relationship between vasculitis and metastasis in kidney-related urogenital cancers: A multicenter real-world propensity-matched cohort study.
720091,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Incidence of adolescent and young adult renal cell carcinoma in the modern era.
720092,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Impact of serum LDH on clinical outcomes in patients with good-risk metastatic non-seminomatous germ cell-cell tumors (NSGCT).
720093,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Prognostic value of baseline serum IgG in metastatic clear cell renal cell carcinoma treated with first-line IOâ€“TKI therapy.
720094,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Performance of circulating tumor DNA as a biomarker in testicular seminoma and non-seminomatous germ cell tumor patients undergoing primary retroperitoneal lymph node dissection.
720095,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Circulating tumor DNA performance in primary retroperitoneal lymph node dissection: A stage-based analysis.
720096,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Prognostic factors affecting racial impact in testicular cancer outcomes in the United States.
720097,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Clinical characteristics and survival outcomes of primary sarcoma of the kidney (PSK).
720098,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Leveraging large language models (LLM) to guide adjuvant treatment recommendations for renal cell carcinoma (RCC) after nephrectomy.
720099,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Bridging global gaps: Expanding GU oncology education through iECHO telementoring.
720100,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Contemporary survival and treatment outcomes in malignant spermatic-cord tumors: A two-decade population-based analysis.
720101,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Second opinions and treatment guidance in non- or minimally metastatic testicular cancer: Is ChatGPT 5 non-inferior to expert recommendations?
720102,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Ethnic disparities and variations in testicular germ cell tumours: A retrospective real-world analysis in a single tertiary cancer centre.
720103,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Artificial intelligence (AI) as a practical decision support tool for oncologists: Genitourinary (GU) cancer cases.
720104,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Conventional-dose chemotherapy as first salvage in germ cell tumors: Outcomes from an Ibero-American multi-institutional cohort.
720105,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Demographic predictors of primary retroperitoneal lymph node dissection (P-RPLND) vs. primary chemotherapy (P-Ch) in the treatment of clinical stage IIA/B (CSIIA/B) non-seminomatous testicular germ cell tumors (NSGCTs).
720106,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Primary retroperitoneal lymph node dissection for clinical stage IIA/B metastatic seminoma: A multi-centre Australian experience.
720107,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Turning the tide in recurrent NSGCT: Retrospective insights into TIP vs non-TIP salvage chemotherapy.
720108,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Benign persistent elevation of alphafoetoprotein (AFP) after curative treatment for germ-cell tumors.
720109,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Serum amyloid A4 and cognitive functioning in long-term testicular germ cell tumor survivors.
720110,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Survivorship outcomes of stage I testis cancer management.
720111,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Impact of bleomycin shortage on real-world outcomes in germ cell tumors: A multicenter retrospective analysis in Brazil.
720112,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Surveillance after complete response (CR) to first-line chemotherapy (chemo) in non-seminomatous germ-cell tumor (NSGCT).
720113,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Subclinical hepatic injury and risk of nonalcoholic steatohepatitis after adjuvant systemic therapy in early-stage testicular cancer survivors.
720114,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Contemporary patterns of treatment and outcomes in germ-cell tumors across a provincial cancer system: British Columbia Germ Cell Tumor Clinical Database.
720115,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Vertebral surgery in the management of complex postchemotherapeutic retroperitoneal lymph node dissection (PC-RPLND).
720116,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Prognostic utility of lactate dehydrogenase in patients with metastatic seminoma.
720117,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Divergent biology and outcomes of somatic transformations (SM) in germ cell tumors (GCT).
720118,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Impact of bleomycin dose omissions on clinical outcomes in non-seminomatous germ cell tumors: A systematic review and meta-analysis.
720119,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Post-chemotherapy retroperitoneal lymph node dissection for patients with metastatic pure seminoma.
720120,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Progression after first-line chemotherapy with normal serum tumor markers (STM) in non-seminomatous germ-cell tumors (NSGCT).
720121,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Oncological outcomes of primary retroperitoneal lymph node dissection in patients with clinical stage IIB seminoma: A binational retrospective analysis.
720122,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",miR-371a-3p as a potential biomarker for monitoring disease activity and therapeutic response in metastatic seminoma and non-seminomatous germ cell tumor patients treated with BEP chemotherapy.
720123,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Surveillance of patients with complete response following first-line chemotherapy for germ cell tumors: Focus on lifestyle, socioeconomic, and sexual health outcomes."
720124,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Relapsed/refractory clinically advanced (CA) testicular non-seminomatous germ cell tumors (NSGCT): A genomic landscape study.
720125,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Parallel liquid biopsy analysis of miR-371a-3p and cell-free DNA in testicular germ cell tumors.
720126,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Circulating tumor DNA (ctDNA) as a real-time biomarker in marker-negative germ cell tumors (GCT): A proof-of-concept study.
720127,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Dose expansion part of the phase II DAREON-5 trial.
720128,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Primary urethral squamous cell carcinoma: Insights and outcomes from a 27-year institutional experience.
720129,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Genomic analyses of bilateral testicular germ cell cancers (BITCOIN study) from the Italian Germ Cell Cancer Group (IGG).
720130,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",A phase 1/2 study to assess peptidomimetic carbonic anhydrase IX imaging and therapy with [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 in patients with advanced clear cell renal cell carcinoma and other solid tumors.
720131,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Use of circulating tumor DNA (ctDNA) in the detection of residual disease and recurrence for patients with testicular cancer.
720132,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",TANKeR-70: TGF-Î²-receptor type 2 knockout allogeneic NK cells for renal cell carcinoma expressing CD70.
720133,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",SWOG S1823/CCTG GCC-01 secondary use of data: North American patterns of care in clinical stage I germ cell tumours.
720134,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",ICON trial: Phase I/II trial of inulin gel in combination with ipilimumab and nivolumab in advanced renal cell.
720135,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Digital monitoring of self-reported symptoms by patients treated with cabozantinib plus nivolumab for advanced clear-cell renal carcinoma (CANIQOL).
720136,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Ivonescimab in metastatic clear cell renal cell carcinoma (mccRCC) after immune checkpoint inhibitor therapy: The phase II IVORY trial.
720137,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors.
720138,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","A multicenter, open-label, phase II study of adaptive combination immunotherapy with VEGFR-TKI for advanced renal cell carcinoma."
720139,"Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Cross institutional comparison of the miR-371a-3p assay in pre-surgical germ cell tumor (GCT) patients.
720140,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Short term intensified pembrolizumab and tivozanib for high-risk renal cell carcinoma: STRIKE! (Alliance A032201).
720141,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","Systemic therapy combined with radiotherapy versus systemic therapy alone for oligometastatic kidney cancer (STROKER): A multicenter, randomized controlled phase III trial."
720142,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","A randomized phase 2 trial of nivolumab, relatlimab plus ipilimumab vs. nivolumab plus ipilimumab in first-line advanced renal cell carcinoma."
720143,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Phase 1b/2 KEYMAKER-U03 substudy 03C of belzutifan plus zanzalintinib or belzutifan monotherapy for recurrent clear cell renal cell carcinoma during or after antiâ€“PD-(L)1 therapy.
720144,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",A phase II study bolstering outcomes by optimizing immunotherapy strategies with evolocumab and nivolumab in patients with metastatic renal cell carcinoma (BOOST-RCC).
720145,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER)."
720146,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Phase 1/2 OMAHA-U01 substudy 01A: Oral CYP11A1 inhibitor opevesostat alone or in combination with other therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
720147,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Phase 1B/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment-naÃ¯ve patients with advanced clear cell RCC.
720148,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",The ITALIC-RCC study: A randomized study of clinical and humoral impact of primary tumor ablation in metastatic renal cell carcinoma treated with immunotherapy.
720149,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Phase 1/2 dose escalation/expansion study of REGN10597 (antiâ€“PD-1â€“IL2RÎ±-IL2) in patients with advanced solid tumors.
720150,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Randomized phase II trial of maintenance oral etoposide versus observation following high-dose chemotherapy and peripheral blood stem cell transplant in relapsed non-seminomatous germ cell tumors.
720151,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
720152,"Innovations in Kidney Cancer in 2026: Diagnostics, Novel Targets, and Trial Design",CYTOSHRINK: A randomized phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
720153,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumor (GCT).
720154,"Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers","ASPIRE GCT: A single-arm, phase II clinical trial of aspirin to prevent venous thromboembolism in patients with advanced germ cell tumors receiving chemotherapy."
720155,Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Ultra-sensitive whole-genome sequencing-based molecular residual disease detection in resectable renal cell carcinoma: Preliminary results from the MONSTAR-SCREEN-3 study.
720156,Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,A phase II trial of cabozantinib in relapsed refractory germ-cell tumors (GCT).
720157,Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Outcome of intermittent or continuous axitinib (axi) in combination with avelumab (ave) for metastatic renal cell carcinoma (mRCC): Insights from the Tide-A and Javelin Renal 101 (JR101) trials.
720158,Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.
720159,Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model.
720160,Rapid Oral Abstract Session C: Renal Cell Cancer and Testicular Cancer,"Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial."
720161,Breakout Session: Optimizing Care for Frail and Older Patients Across the Spectrum of Genitourinary Cancers,Understanding and Overcoming Frailty in the Care of Patients With Genitourinary Cancers
720162,Breakout Session: Optimizing Care for Frail and Older Patients Across the Spectrum of Genitourinary Cancers,Oncologic Care in Older Patients With Genitourinary Cancers
720163,Breakout Session: Optimizing Care for Frail and Older Patients Across the Spectrum of Genitourinary Cancers,Panel Discussion With Audience Question and Answer
720164,Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer,What Do Patients With Prostate Cancer Really Care About?
720165,Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer,Minimizing Harm: Surgical Approaches to Preserve Continence and Sexual Function
720166,Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer,Precision Matters: How Radiation Choices Shape Quality of Life
720167,Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer,"The Hidden Burden for Patients: Depression, Anxiety, and Decision Regret in Prostate Cancer Care"
720168,Balancing Cure and Quality: Navigating Functional Outcomes in Localized Prostate Cancer,Panel Question and Answer
720169,Keynote,Introduction of Keynote Speaker
720170,Keynote,Reimagining Cancer Research and Care in the Age of Artificial Intelligence
720171,Keynote,Question and Answer
720172,Multidisciplinary Tumor Board: From Imaging to Molecular Insightsâ€”Tailoring Therapy Intensity in Localized/Locally Advanced Prostate Cancer,Panel Discussion With Audience Question and Answer
720173,Poster Walks: Prostate Cancer,Poster Walk Leader
720174,Poster Walks: Prostate Cancer,Poster Walk Leader
720175,Breakout Session: Multidisciplinary Care of Patients With Penile Cancer,Surgical Strategies for Penile Preservation
720176,Breakout Session: Multidisciplinary Care of Patients With Penile Cancer,"Lymph Node Dissection for Penile Cancer: When, How, and How Much?"
720177,Breakout Session: Multidisciplinary Care of Patients With Penile Cancer,Medical Management of Advanced Penile Cancer
720178,Breakout Session: Multidisciplinary Care of Patients With Penile Cancer,Panel Question and Answer
720179,Pathways to Publication: Connect With ASCO Journal Editors Networking Luncheon,Journal of Clinical Oncology
720180,Pathways to Publication: Connect With ASCO Journal Editors Networking Luncheon,JCO Global Oncology
720181,Pathways to Publication: Connect With ASCO Journal Editors Networking Luncheon,JCO Oncology Practice
720182,Pathways to Publication: Connect With ASCO Journal Editors Networking Luncheon,JCO Oncology Advances
720183,Bladder Cancer in Women: Bridging Gaps in Science and Solutions,Unequal Burden: Sex Differences in Bladder Cancer Presentation and Prognosis
720184,Bladder Cancer in Women: Bridging Gaps in Science and Solutions,Biological Differences Underlying Sex and Gender Disparities in Bladder Cancer
720185,Bladder Cancer in Women: Bridging Gaps in Science and Solutions,Sexual Dysfunction in Women After Local Radiation Therapy for Bladder Cancer
720186,Bladder Cancer in Women: Bridging Gaps in Science and Solutions,Sexual Dysfunction in Women After Local Surgical Therapy for Bladder Cancer
720187,Bladder Cancer in Women: Bridging Gaps in Science and Solutions,Panel Question and Answer
720188,Poster Walks: Urothelial Carcinoma,Poster Walk Leader
720189,Poster Walks: Urothelial Carcinoma,Poster Walk Leader
720190,"Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Poster Walk Leader
720191,"Poster Walks: Renal Cell Cancer; Adrenal, Penile, Testicular and Urethral Cancers",Poster Walk Leader
720192,Multidisciplinary Tumor Board: Challenges and Opportunities in Treating Patients With Advanced Kidney Cancer,Panel Discussion With Audience Question and Answer
